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NUCLEOTIDE EXCISION REPAIR, CROSSLINK REPAIR AND 
TRANSCRIPTIONAL FUNCTION OF XPA IN HUMAN CELLS 
 
Mandira Manandhar, PhD 
Supervisory Professor: Richard D. Wood, PhD 
 
Nucleotide excision repair (NER) in mammalian cells includes xeroderma 
pigmentosum group A protein (XPA) as a core factor. XPA and other NER 
proteins have been detected previously at some active promoters, and NER 
deficiency is reported to decrease activated transcription of selected genes. To 
determine the global extent of XPA influence on transcription, we analyzed the 
human transcriptome by RNA sequencing. We first confirmed that XPA is 
confined to the cell nucleus even in the absence of external DNA damage, in 
contrast to previous reports that XPA is normally resident in the cytoplasm and is 
imported following DNA damage. We then analyzed four genetically matched 
human cell line pairs deficient or proficient in XPA. At a false discovery rate of 
0.05, 325 genes were common in all four pairs with a significant XPA-dependent 
directional change in gene expression. These genes were highly represented in 
pathways for the maintenance of mitochondria, metabolism and neurological 
system. Only 27 genes were regulated by more than 1.5 fold change. The most 
significant hits were AKR1C1 and AKR1C2, involved in steroid hormone 
metabolism, and the corresponding proteins were lower in XPA-deficient cells. 
Transactivation by retinoic acid caused a modest enrichment of genes involved in 
vii 	  
transcription-related functions in XPA proficient cells. The results show that XPA 
status significantly influences a small subset of human genes that are important 
for mitochondrial and metabolic functions. The results may help explain defects 
in neurological function and sterility in individuals with xeroderma pigmentosum 
(XP). 
 
 An NER deficiency enhances sensitivity of mammalian cells to DNA 
interstrand crosslinks (ICL)-generating agents. I found that XPA is retained on 
damaged DNA following exposure to UVA-activated psoralen, and investigated 
repair of a triplex forming oligonucleotide (TFO)-directed psoralen ICL. A TFO-
directed psoralen DNA ICL was constructed in closed-circular DNA. In NER 
proficient human cell extracts, incisions were detected on both strands of the 
damaged DNA 3’ to the psoralen ICL. Incision sites on the TFO bound strand 
were flanked by incision sites 40-42 nucleotides away from the ICL, with incisions 
10-12 nucleotides away on the other strand. 
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Chapter 1. Introduction 
 
1.1. DNA-interstrand crosslink in mammalian cells 
 
  DNA-interstrand crosslinks (ICLs) form a bridge between the two strands 
of the DNA double helix, blocking transcription and DNA replication (Figure 1). 
ICLs are formed by exogenous sources such as mitomycin C (MMC), nitrogen 
mustard, cisplatin compounds and natural compounds such as psoralen. 
Endogenous metabolites also form ICLs, including nitric oxide and the lipid 
peroxidation products acrolein, crotonaldehyde and malondialdehyde (1, 2). ICL-
inducing agents are among the most genotoxic and mutagenic compounds as 
compared to agents that introduce only monoadducts (3). ICL-causing nitrogen 
mustards such as cyclophosphamide and melphalan are widely used for the 
treatment of leukemia as well as solid tumors. Similarly mitomycin C, cisplatin 
and carboplatin are used for treating testicular and ovarian cancers and psoralen 
is used to treat cutaneous T cell lymphoma (2). 
 
  However, it is not fully understood how these ICLs are processed in 
mammalian cells. In replicating cells, the Fanconi anemia pathway plays major 
role in the ICL repair.  The FA complex consists many proteins and 8 of them 
(FANCA, B,C,E,F,G,L and M) form a core complex. Ubiquitination of FANCD2 
and FANCI by the core complex occurs upon encountering ICL blockage, which 
activates the repair process (4). Initially FANCM makes a complex with FAAP24 
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protein that causes the activation of the recruitment of other FA proteins to the 
damage site. These proteins form a complex and stabilize the replication fork, 
which activates ATR mediated cell cycle signalling (5-7). Monoubiquitination of 
FANCD2 is the key for the recruitment of nucleases such as FAN1 and SLX4 (8, 
9). ERCC1-XPF complex and MUS81-EME is also assembled for the processing 
of the ends and the unhooking of the crosslink (6). The unhooked structure is 
cleaved by NER (10, 11) and the double strand break is repaired through 
homologous recombination (HR) (12, 13). Translesion synthesis (TLS) 
polymerases like Rev1-Rev3L are involved in NER process after unhooked 
structures are removed (14) and FA complex is necessary for their recruitment 
(15, 16).  
 
  There is also evidence that nucleotide excision repair (NER) is an 
important repair pathway for ICL in nonreplicating cells. NER dual incision is well 
studied in E. coli. In mammalian cells, NER deficient cells are sensitive to ICL 
inducing agents (10, 17, 18) . Also, ICL repair defects have been shown in NER 
defective cells by various researchers. ICL formed by psoralen could not be 
removed in XPA deficient cells in a gene specific assay (19). XPA and XPF 
defective ceIls were defective in unhooking ICL formed by psoralen (18) and 
formed by cisplatin in XPG defective cells (20).  
 
  Incision is an important step in the processing of ICL as it determines how 
ICL will be being processed. Some studies have been done focusing on incisions 
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around ICLs. Bessho et al (1997) found that NER in human cell extracts 
introduced two incisions separated by about 21 nt on the 5’ side of a psoralen 
ICL (21). Smeaton et al. (2008) used a crosslink placed in a 150-mer linear 
duplex and verified the presence of these futile incisions (22). They also 
suggested that strong incisions were present about 1-5nt on the 5’ side and 3-5nt 
on the 3’ side of an ICL. The origin of these incisions is not known. Either they 
are artifacts produced by unsuitable ICL substrates for incision assays or if they 
are real, they should be further studied to find their role in the processing of an 
ICL. R. Legerski found a repair patch in a circular psoralen ICL substrate that 
runs from 5’ side to 3’ side of the ICL suggesting a dual incision (23). Thus a very 
controlled and precise mapping study of ICL repair in mammalian cells is 
necessary in order to fully understand the mechanism of ICL processing. This 
understanding will allow the manipulation of different steps of processing of an 
ICL. 
 
  ICL forming agents have been effective in treating some forms of cancer, 
but they are not so useful in others. In addition, resistance to ICL forming 
chemotherapies is a major problem for treatment of cancer. This problem could 
be solved to a greater extent, if we understood the details of processing of ICL.  
Study of the repair of a site-specific ICL is a controlled way of exactly mapping 
out how cells process ICL damage. 
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  A psoralen ICL was studied here, targeted by a triplex-forming 
oligonucleotide (TFO). In addition to directing psoralen to a specific site of DNA, 
TFOs have a very important therapeutic potentiality. TFOs can be used to 
targeted gene alterations. For example, TFO mediated correction of AID deficient 
human lymphocytes and p53 mutant glioblastoma cells have been demonstrated 
(24). There are also studies showing that a TFO might enhance the recruitment 
of repair proteins. In E. coli, a TFO-directed psoralen ICL is an NER substrate 
and leads to significantly more incision products than psoralen by itself (25). NER 
was indicated to be involved in TFO mediated homologous exchange, and 
sequence specific mutagenesis was shown to be dependent on the NER protein 
XPA (26, 27).  
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FIGURE 1. Chemical structure of psoralen DNA ICL and space filling model 
of a TFO-psoralen DNA ICL 
A. Structure of an interstrand crosslink formed by HMT psoralen on thymines (T) 
on both strands of DNA. The furan ring of psoralen binds to one thymine and the 
pyrone ring of psoralen binds to a thymine on the complementary DNA strand. B. 
Space filling model of TFO binding to duplex DNA in the major groove. Yellow 
indicates psoralen bound at 5’ end of the TFO, green and blue indicate two 
strands of DNA. 
FIGURE 1B is adapted from Christensen LA, Wang H, Van Houten B, Vasquez 
KM: Efficient processing of TFO-directed psoralen DNA interstrand crosslinks by 
the UvrABC nuclease. Nucleic Acids Res 2008, 36(22): 7136-7145. 
Permission has been acquired from the journal to use this figure. 
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1.2. Nucleotide excision repair pathway and XPA protein 
 
 Nucleotide excision repair is the DNA repair pathway for a wide range of 
DNA lesions. The lesions include pyrimidine dimers formed by UV radiation, and 
bulky adducts formed by many chemicals and some endogenous metabolites (28, 
29). NER has two sub-pathways: Global genomic NER (GG-NER) and 
transcription coupled NER (TC- NER). The difference in the two pathways lies in 
the recognition of the damage. GG-NER recognizes the distortion in the helix of 
DNA in all parts the genome. TC-NER is activated when RNA polymerase II is 
stalled during the elongation of transcript due to the presence of DNA damage on 
the template strand. The overall function of mammalian NER is to precisely 
remove the damaged nucleotides as a 24-32 base long single-stranded 
oligonucleotide and then to restore the DNA with undamaged nucleotides. About 
30 polypeptides are involved in the whole process of NER, which make 
successive complexes necessary for damage recognition, incision and 
restoration (28, 30, 31) (Figure 2).  
 
  In GG-NER, the initial damage recognition is done by protein complex 
called XPC-RAD23B (32). XPC is sequestered by damaged DNA and its binding 
to damaged DNA triggers the further repair process (32). RAD23B enhances the 
DNA binding activity of XPC, stabilizes the complex and protects it from 
proteasome degradation (28). It does not come in direct contact with DNA and is 
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not immobilized on the damaged DNA but it is released after XPC binds to the 
DNA (33). An N-terminal region (amino acids 154-334) of XPC binds to XPA (34).  
  
  After DNA distortion is recognized, TFIIH is recruited to the damaged site. 
TFIIH is a ten subunit complex consisting of proteins XPB, XPD, p62, p44, p34, 
p52, p8 and a cdk activating kinase (CAK) with subunits Mat1, Cdk7 and CyclinH. 
TFIIH is a general transcription factor but also acts as a core NER factor for DNA 
repair. The XPB subunit of TFIIH is a 3’à5’ DNA helicase and XPD is a 5’à3’ 
helicase. TFIIH unwinds DNA at the damaged site to form a single stranded 
region, in an ATP dependent manner (35, 36). RPA and XPA interact with TFIIH 
in the pre-incision complex. RPA is a single stranded DNA binding protein and 
consists of 3 subunits with multiple cellular functions (37). RPA helps to form a 
stable pre-incision bubble with four functional DNA binding OB 
(oligonucleotide/saccharide binding)-folds present in its p70 and p32 subunits. 
These interact with DNA in a polar manner (5’à3’) (38, 39). They occupy 30 
nucleotides on the undamaged strand and thus protect this strand from 
degradation by nucleases as well as facilitate the precise positioning of the 
endonucleases at 5’ and 3’ side of the adduct.   
 
  XPA protein has increased affinity towards DNA structures such as 
distortion of the helix due to damage of DNA. Thus XPA is part of the 
confirmation process that detects the structural DNA distortion caused by DNA 
damage (40). It directly interacts with damaged DNA (41, 42) at the junction of 
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single strand and double strand (43). XPA is recruited to the damaged site by 
TFIIH complex through its p8 and p52 subunits (44, 45). Interestingly XPA is also 
reported to interact with another transcription factor TFIIE, however the function 
of the interaction is not clear (46). XPA is a small protein with 273 amino acids, 
does not have any enzymatic activity but interacts with other NER proteins 
playing role as a major scaffolding protein in NER. XPA coordinates with RPA to 
facilitate the functions of nucleases for NER.  
 
   XPA has a globular central domain (98-219) with a C4 type zinc finger 
motif in the N terminal region and a cleft in the C-terminal region. XPA has many 
protein binding interaction domains (47-50) (Figure 3). Interestingly XPA point 
mutations associated with xeroderma pigmentosum are principally in the central 
domain (50, 51). Mutations compromising or eliminating the DNA binding region 
are associated with the most severe XP syndromes including accelerated aging 
and neurodegeneration (51). XPA also interacts with XPE at XPA residues 185-
226, and the mutation at this site has been reported to cause failure in the 
removal of cyclobutane pyrimidine dimers (CPD) (52). XPA interacts with RPA2 
primarily via XPA residues 29-46 and XPA residues 98-219 secondarily or 
weakly interact with RPA1 (49, 53).  XPA has a nuclear localization (NLS) 
domain at 30-42 aa region. However it has been shown that when mutation of 
XPA at this region affects its localization in the nucleus, these residues were not 
found to be essential for DNA repair (54).  
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  ERCC1-XPF nuclease is recruited to the damage site by interaction of 
XPA protein amino acids 96-114 and ERCC1 residues 92-119 (48).  
XPA contains a PCNA binding site called an APIM (AlkB homolog PCNA 
interacting motif) sequence but the functional aspect of the interaction is not clear 
yet (55). XPA also interacts with other proteins such as ATR and PARP that are 
not involved in NER. ATR phosphorylates XPA at Ser196. XPA has a PARP 
binding motif at 213-237. PARP can inhibit the DNA binding activity of XPA (56). 
 
  Mutations in XPA cause XP, with a severity that varies according to the 
particular mutation. A common consequence of XPA mutations is sensitivity to 
UV radiation, leading to skin abnormalities and a predisposition to skin cancers. 
The most severe cases result in progressive neurodegeneration and a higher 
incidence of melanomas (57-59). The reason behind the variation in the severity 
in the XPA deficient patients is still to be studied. This could be the result of 
expression of different fragments of XPA protein with different functions.  
Truncation of Exon 1 or Exon 6 which is thought to be dispensable for NER, have 
been reported to yield only mild XP syndrome whereas deletion of Exon 2-5 
which encodes the DNA binding domain and is essential for NER has been 
reported to cause a severe form of XP (51, 60, 61).  
 
  ERCC1-XPF and XPG are structure specific endonucleases that cleave 
on the 5’ side and 3’ side of an adduct on the damaged DNA strand during 
nucleotide excision repair. ERCC1-XPF protein has multiple functions besides a 
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role in NER. The endonuclease activity of this complex can act on different 
substrates including those formed by the Fanconi anemia pathway during repair 
of ICL-induced DNA damage, 3’ ends during homologous recombination and 
hairpin structures (62), removal of non-homologous ends during non-homologous 
end joining (63-65) and maintenance of telomeres (62, 66). Disruption of ERCC1 
has severe consequences. Mice with disrupted ERCC1 die before weaning from 
liver disorder and other organ failure (67, 68). Mice with a knock out of the XPG 
gene die due to a developmental defect in intestine formation (69) and humans 
with XPG mutations sometimes have a short life-span and developmental defects 
similar to Cockayne syndrome, indicating that XPG has a second function other 
than in NER (70).  
 
  CSA and CSB proteins are essential for transcription coupled NER. 
Mutation in CSA and or CSB genes cause a severe condition called Cockayne 
syndrome which is characterized by severe neurodegeneration, developmental 
defects, accelerated aging (progeroid syndrome) and UV radiation sensitivity (71). 
The mixed cases of CS/XP are even worse, with both CS and XP symptoms 
caused by specific mutations in the XPB, XPD or XPG genes. These individuals 
have an increased photosensitivity and more cancer-proneness as they have 
defects in both TC-NER and GG-NER (71). 
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FIGURE 2.  Diagram of NER in mammalian cells showing stepwise events. 
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This diagram shows the GG-NER pathway. (i) XPC-RAD23B protein complex 
recognizes the distortion of DNA helical structure caused by the lesion. TFIIH is 
recruited by XPC-RAD23B complex at a site of damage. (ii) The NER proteins 
XPA, RPA, XPG and ERCC1-XPF are recruited at the damaged site to form a 
preincision complex together with TFIIH complex. The two DNA strands are 
separated in an ATP dependent manner to form a bubble (72). (iii) The ERCC1-
XPF nuclease makes an incision at the 5’ side of the lesion and the XPG 
nuclease produces the incision at the 3’ side. This process of producing incision 
at both sides of the lesion simultaneously is referred as dual incision.  The CDK7-
activating (CAK) subunits of TFIIH are detached from the precision complex after 
it is formed (73). Dual incision releases a fragment of damaged DNA about 27-32 
nucleotides long. This is a characteristic of NER in mammalian cells. (iv) A DNA 
polymerase is loaded by PCNA and fills the gap made by the incisions. 
 
FIGURE 2 is adapted from Wood, R. D. (2010): Mammalian nucleotide excision 
repair proteins and interstrand crosslink repair. Environ Mol Mutagen 51(6): 520-
526 
 Permission has been acquired from the journal to use this figure. 
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1.3. Transcriptional role of XPA, a major NER protein  
 
  Nucleotide excision repair (NER) is the only pathway that mammalian cells 
have available for the removal of DNA lesions arising from ultraviolet (UV) 
radiation damage. NER also repairs helix-distorting lesions produced by other 
types of radiation and some chemicals. In eukaryotes, most of the components of 
the NER machinery have major additional biological functions that are essential 
for normal viability. This has profound consequences for cells or organisms with 
mutations in NER genes. The ten subunits of TFIIH form a core initiation factor 
for basal transcription of all mRNAs, for example, and XPG also has a 
transcription-related function (74). ERCC1-XPF participates in some homologous 
recombination reactions and in crosslink repair (62). As a consequence, 
complete disruption of some NER components is incompatible with cellular 
survival or embryonic development (for example, TFIIH subunits or RPA), while 
perinatal lethality occurs following disruption of other components (ERCC1, XPF, 
XPG). Mutations that partially disable these factors can lead to severe diseases 
in human beings. 
 
  Complete disruption of two major NER factors is tolerated, however. One 
of these is XPC, part of a distortion recognition complex. XPC disruption causes 
xeroderma pigmentosum in humans, but is relatively less severe than other 
forms because a transcription-coupled form of NER remains intact. Nevertheless, 
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even XPC is reported to play a dual function as a component of a transcription 
complex for specific genes (75). 
 
  The other NER factor that can be completely inactivated without impairing 
cell viability is XPA. This is notable, as XPA is absolutely required for NER. It is a 
scaffold protein that contacts many of the other factors in NER and binds to DNA 
(Figure 3). As a consequence, xeroderma pigmentosum (XP) group A patients or 
mice without XPA function have no NER activity. Because each of the other NER 
factors has an identified additional function in cells, it is important to consider 
whether XPA also has a significant biological function other than NER. Broadly, a 
complete XPA defect has no major effect on mammalian development, growth or 
cellular function. Patients with mutations that completely ablate XPA function are 
born, develop normally and live for several decades. Similarly, mice with 
complete XPA defects are born, develop normally, and have a near-normal 
lifespan, with a low background of spontaneous tumors occurring later in life. 
 
  XPA patients often succumb to metastatic UV radiation-induced skin 
tumors. This can be delayed by protection of individuals from sun exposure. In 
addition, many XPA patients with loss of XPA function show accelerated 
neurological deterioration over decades, initially characterized as de Sanctis-
Cacchione syndrome (57). Retention of a small amount of XPA function results in 
much milder symptoms (76). A likely explanation for the origin of the neurological 
impairment is the accumulation of genomic DNA lesions over decades in non-
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replicating neural cells that can only be repaired by NER (77). Prime candidates 
are the cyclopurines (78) induced by reactive oxygen species, which are repaired 
by NER and cannot be removed by other repair systems (78, 79). XPA-defective 
mice, with a much shorter lifespan, do not appear to exhibit these neurological 
deficits (80). 
 
  Nevertheless, a few observations have suggested that XPA might have 
additional functions beyond NER. At several tested promoters, all NER proteins 
including XPA can be detected by chromatin immunoprecipitation. The basal 
transcription factor TFIIH is expected to be present at promoters, and XPA may 
be detectable because it binds to TFIIH and associated proteins. However at 
least one result indicated that XPA depletion affects retinoic acid (RA) – induced 
transcription of some genes (81). Indeed, depletion of XPA reduced RA-activated 
transcription of RARB, PPAR, and HMGCS2. Moreover, a study comparing XPA 
proficient and deficient cells by microarray analysis found changes in gene 
expression associated with XPA status, and indicated that XPA-deficient cells 
have mitochondrial dysfunction with defects in pathways of mitophagy (82), a 
condition that could impact neural health. Decline of mitochondrial activity is the 
hallmark of many neurological diseases, and neurons are the most sensitive to 
mitochondrial dysfunctioning (83). These studies indicate the possibility of 
mitochondria being affected when NER proteins are defective. The syndromes 
observed in NER-deficient cases in humans and mice are mainly due to the 
inability to repair DNA damage but more studies are necessary to understand the 
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mechanisms of all the syndromes. An RNA- sequencing study on XPD/CS 
patient cells, after UV exposure, suggests that the syndromes are not solely due 
to DNA repair defects but also due to other transcriptional dysfunctioning (84). It 
is very intriguing to see if a defect in NER proteins causes significant changes in 
expression of genes in human cells. 
 
  Nucleotide excision repair (NER) proteins XPC, XPA, ERCC1-XPF, XPG, 
TFIIH and CSB have also been reported to play an important role in the 
regulation of nuclear receptor-dependent genes (81, 84-88). Down regulation of 
any of these NER factors have shown to decrease the transcription of several 
genes as well as impeding of the recruitment of the other NER factors at the 
transcription sites (85). It is interesting that NER proteins play a significant role in 
modulating the transcription of some genes and raises the question of whether 
the whole genome is affected.  
 
  However, no study has been done in order to pursue genome wide 
changes in the transcriptome in absence of specific NER proteins in absence of 
any genotoxic challenge. To specifically investigate the extent of a possible 
transcriptional defect in XPA-deficient cells, we examined genome wide 
expression of transcribed genes by RNA-Seq analysis.  
 
  Based on previous studies (81, 82, 85-88), we expected that an XPA 
defect might result in down regulation of genes responsible for mitochondrial, 
17 	  
metabolic and neurological functions. We also transactivated cells with retinoic 
acid (RA), which is the ligand for receptors including PPAR and RAR. The 
products of the genes expressed by the activation of these receptors are involved 
in many cellular functions such as cell differentiation, cell proliferation, apoptosis 
and metabolism.  
 
1.4. Localization of XPA protein 
 
  As described above, XPA has multiple functions, including a novel 
transcriptional role, which we are actively pursuing. In order to have a direct role 
as a transcription factor, XPA would have to be present in the nucleus where 
transcription takes place. Although XPA is localized in the nucleus under 
standard fixation conditions, we were concerned about reports that XPA is 
normally resident in the cytoplasm, and is only recruited to nuclei following UV 
radiation exposure (89, 90). Notably, in those studies, cells were first briefly 
exposed to wash buffers containing Triton X-100 detergent or the milder fixation 
agent methanol (89, 91), or with 0.05% NP-40 detergent (90). It is possible that 
previous observations suggesting nuclear import of XPA following UV radiation 
may have been misinterpreted because of nuclear leakage. 
 
  Nuclear pores are complex structures composed of 50 -100 different 
proteins in vertebrates, making large pores through which small proteins less 
than 50 kDa can passively pass. Nuclear pores have a diameter of about 120 nm 
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and a molecular weight of about 125 million dalton (Da) (92). Detergents used in 
different cellular studies can form micelles in the nuclear membrane and make it 
even easier for the small proteins to leak out of the nucleus. The permeabilization 
with detergents like NP-40 or Triton-X-100, which are non-selective in nature 
could lead to false results regarding the localization of the proteins (93). Studies 
have shown leaking of unassembled proteins from the nucleus to the cytoplasm 
by detergent extraction (94).  
 
  UVC radiation exposure to cells leads to two major kinds of DNA 
photoproducts (6-4) photoproducts and cyclobutane pyrimidine dimers (CPD) (95, 
96).  80% of the adducts are CPDs and 20% are 6-4 Photoproducts (6-4PP) (29, 
97). XPA is involved strongly in repair of these photoproducts as NER pathway is 
the major DNA repair pathway for both kinds of DNA damage. We hypothesized 
that during the repair process, XPA may be strongly recruited to sites of DNA 
damage, inhibiting leakage even following the use of detergent. This would give a 
different interpretation than hypothesizing that XPA is imported to the nuclei after 
exposure to UV radiation.  
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At the top, the diagram shows human XPA protein with location of the central 
globular core in relation to the six coding exons (gray). The locations of the 
nuclear localization signal (NLS) and zinc finger (Zn2+) are shown. The bottom 
part of the panel shows mapped regions of XPA that interact with other proteins.  
 
FIGURE 3 is adapted from Sugitani N, Sivley RM, Perry KE, Capra JA, Chazin 
WJ: XPA key scaffold for human nucleotide excision repair. DNA Repair (Amst) 
Permission has been acquired from the journal to use this figure. 
 
  
FIGURE 3: Diagram of XPA with the interaction with other proteins 
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Chapter 2. Methods and Materials 
 
2.1. Preparation of samples for the next generation sequencing of RNA 
from XPA deficient and proficient human cell lines  
 
2.1.1. Cell lines 
 
Four human cell lines deficient in XPA and their complementary XPA-
proficient cell lines were used. SV40-immortalized human fibroblast cells from 
patients deficient in XPA (XP12RO and XP2OS) (98) and XPA-proficient 
(XPA/XP12RO and XPA/XP2OS) cell lines complemented with XPA cDNA were 
kindly provided by Dr. Masafumi Saijo, Osaka University. The mutations in 
XP12RO and XP2OS are also shown in Figure 4A. Only 10% of our initial culture 
of XPA/XPA12RO cells expressed XPA as shown by an immunofluorescent 
assay with 12F5 anti-XPA antibody. We recloned XPA/XP12RO obtaining clone 
2, which uniformly expresses XPA. All experiments reported here used clone 2 of 
XPA/XP12RO as the XPA-proficient cell line paired with XP12RO.  HeLa S3 cell 
line was from laboratory stock. XPA disrupted HeLa S3 cell lines KO142 and 
KO38 were derived by CRISPR-Cas9 targeting technology by the Gene Editing 
and Cellular Model Core Facility at the University of Texas MD Anderson Cancer 
Center (Figure 4B). XP12RO and XP2OS and the complemented XPA cell lines 
were grown in DMEM-high glucose (Sigma D5796) and HeLa S3, KO142 and 
KO38 in RPMI-1640 25 mM HEPES (Sigma R4130) medium. All cells were 
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grown in medium containing 10% FBS, 1% streptomycin/penicillin solution at 37 
ºC and 5% CO2. 
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A. The exon-intron structure of the human XPA gene showing the sites of the 
causative XPA mutation in each XPA-deficient cell line used here. B. Location of 
CRISPR-Cas9 mutations generated in the XPA gene of HeLa S3 cells. Two 
mutated HeLa cell lines were obtained using two guide RNAs (gRNA). KO142 
had the indicated 18 bp deletion in both alleles, and an A164G mutation leading 
to a Q16R amino acid change in one allele. KO38 had a deletion of C168 
(∆C168) leading to early termination in both alleles and a C142T mutation 
leading to a P9S amino acid change in one allele.  
	    
FIGURE 4. XPA disruption in proficient and deficient cell lines used in the 
study. 
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2.1.2. Immunoblotting 
 
Anti-XPA antibodies used were rabbit polyclonal CJ1 (99), mouse 
monoclonal 12F5, and rabbit polyclonal GTX103168 (Cat. No. GTX103168, 
GeneTex). Other antibodies used were mouse monoclonal to AKR1C1 (Cat. No. 
GTX53684, GeneTex), rabbit polyclonal to AKR1C2 (Cat. No. 13035, Cell 
Signalling Technologies Inc.), rabbit polyclonal to AKR1C3 (Cat. No. ABS1172, 
EMD Millipore), and mouse or rabbit α-tubulin (Sigma Aldrich). Mouse 
monoclonal 1E4 (Trevigen) to XPF was a gift of Dr. Laura Niedernhofer. Cell 
lysates were prepared by lysing 106 or 107 cells in lysis buffer (500 mM KCl, 20 
mM Tris–HCl [pH 8.0], 5 mM MgCl2, 10% glycerol, 1 mM PMSF, 0.1% Tween 20, 
10 mM β-mercaptoethanol) by pipetting up and down and then sonicated on ice 
(45 sec with 15 sec intervals, for 2 times at 1 amplitude). Lysates were then 
mixed with SDS loading buffer for 3 min at 95 °C before loading onto a 4-20% 
gradient polyacrylamide gel. Proteins were transferred to a PVDF (polyvinylidene 
fluoride membrane) for 1 hr in transfer-buffer (Tris-glycine with 20% methanol) 
cooled on ice. The blots were blocked with 10% non-fat dairy milk for 2 hr at 
room temperature and washed 3 x 10 min with TBS-T (Tris buffered saline-
Tween 20). Membranes were incubation with primary antibodies diluted as 
follows (CJ1; 1: 10000, 12F5; 1: 5000, GTX103168; 1: 1000, XPF 1E4; 1:2000, 
AKR1C1; 1:1000, AKR1C2; 1: 500, AKR1C3; 1: 1000, α-tubulin; 1:8000). 
Membranes were incubated overnight at 4 °C except for tubulin, which was for 20 
minutes at room temperature. Then they were washed 3 x 10 min and incubated 
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with mouse or rabbit IgG secondary antibodies (1:10,000) at room temperature 
for 2 hr, washed and treated with Pierce Western blot signal enhancer (Thermo 
Scientific Inc.) and then exposed to x-ray film.  
 
2.1.3. UVC clonogenic survival assay 
 
The UVC clonogenic survival experiments were performed using two 15 W 
germicidal lamps emitting predominantly 254 nm light adjusted to a fluence of 0.3 
J/m2/s. Cells were plated onto 10 cm dishes at densities of 1-5x105 cells per plate 
and incubated overnight prior to treatment. The plates were swabbed around 
their perimeters with sterile cotton swabs, growth media aspirated, the attached 
cells rinsed once with sterile phosphate buffered saline without magnesium or 
calcium (PBS) and irradiated with lids off through 4 ml of PBS. Following 
treatment, the PBS was aspirated and cells were detached by trypsin-EDTA 
treatment, passed through a 23 gauge needle, diluted, counted using a Beckman 
Coulter Particle Counter Z1 Single, and plated at the appropriate cell number for 
the given dose, in triplicate, into 10 cm plates containing 10 mL of growth 
medium. Following incubation for 12-17 days, colonies were rinsed with PBS, 
fixed with methanol, stained with 0.5% crystal violet in ethanol and counted 
manually. The original plating counts and colony counts were used to determine 
the plating efficiency and the % survival. 
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2.1.4. NER extracts and assays 
 
Whole cell extracts of HeLa S3 and KO38 were prepared as described 
(100, 101). A protein concentration of at least 20 mg/ml was obtained in each 
extract. A single 1,3 (dGpTpG) cisplatin intrastrand adduct substrate was 
prepared and tested in an NER dual incision assay using the end-labelling 
method (102, 103). Briefly, the reaction mixture (10 µl) consisted of 50 ng of Pt-
GTG or control substrate, 40-45 µg of whole cell extract protein, in the NER 
buffer with final concentration of 45 mM HEPES-KOH (pH 7.8), 70 mM KCl, 7.5 
mM MgCl2 , 0.9 mM DTT, 0.4 mM EDTA, 2 mM ATP, 2.5 µg of creatine 
phosphokinase, 3.4 % glycerol and 18 µg of bovine serum albumin. An 
oligonucleotide containing G-overhang was used to detect the dual incision 
product by incorporating complementary [α- 32P] dCTP. NER dual incision 
complementation was done using purified XPA protein. For XPA purification, cell 
growth, induction, and lysis was performed as described (104). The sonicate was 
spun down at 15,000 x g, 30 min at 4 oC. Supernatant was incubated with HIS 
Select Nickel Affinity Gel (Sigma) for 3 hr at 4 oC. The protein was eluted by 
gravity flow with buffer containing 50 mM sodium phosphate (pH 8.0), 100 mM 
KCl, 0.01% NP 40, 1 mM EDTA, 10% glycerol, and 250 mM imidazole. Fractions 
were pooled and the buffer was exchanged to 25 mM HEPES KOH (pH 7.8), 
10% glycerol, 0.4 mM EDTA, 1 mM DTT, and 0.5 M KCl. 
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2.1.5. Immunofluorescence assay 
 
Cells were washed 3 x 3 min with phosphate buffer saline (PBS) followed 
by fixation with 4% formaldehyde for 10 min at room temperature. The fixed cells 
were washed twice with 0.2% Triton-X 100 in PBS at room temperature for 3 min 
followed by washing twice with PBS for 3 min. The cells were blocked with 5% 
normal goat serum for 30 min at room temperature followed by two washes with 
PBS for 3 min each. Incubation with 1:10,000 dilution of anti-XPA antibody 12F5 
was done overnight at 4 °C on a shaker. Followed by a wash with PBS and 
incubation with goat anti-mouse Alexa-Fluor 488 labelled IgG at a 1: 2000 
dilution at room temperature for 2 hr, washed with PBS, incubated 10 min with 1 
mg/ml DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride from Molecular 
Probes) and washed with PBS. The slides were covered with mounting media 
and then coverslips. 
 
2.1.6. XPA-extraction immunofluorescence assay 
 
In experiments observing extraction of XPA from the nucleus into the 
cytoplasm, the cells were exposed to 0.05% NP-40 detergent in PBS for 10 sec 
twice and fixed immediately with 4% formaldehyde for 10 min at room 
temperature followed by two washes of 3 min each with PBS. The fixed cells 
were blocked with 5% goat serum and staining was accomplished as described 
above for normal immunofluorescence. 
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2.1.7. UVC exposure 
 
40,000 cells were plated on 18 mm x 18 mm coverslips in 35 mm diameter 
petri dishes. After overnight incubation, the plates were washed twice with PBS 
for 3 min each time and exposed to UVC for 5 J/m2, 20 J/m2 or 60 J/m2. Medium 
was added back to the cells and incubated for 1 hr at 37 °C. Immunofluorescent 
analysis was carried out as described above.  
 
2.1.8. PUVA treatment 
 
40,000 cells were plated on 18 mm x 18 mm coverslips in 35 mm diameter 
petri dishes at 37 °C overnight. Cells were washed twice with Hank’s balanced 
salt solution (HBSS) and incubated with 10 µM of 4'-Hydroxymethyl-4,5'-8-
trimethylpsoralen (HMT) in HBSS or HBSS alone for 30 min at 37 °C. The cells 
were exposed to UVA for 30 min at 10 J/m2/s and washed with HBSS to remove 
free psoralen.  A second UVA dose of 18 kJ/m2, 36 kJ/m2, 54 kJ/m2 or 10.8 kJ/m2 
was delivered to the cells on plates on ice.  Media was placed back on the plates 
and incubation continued for 1 hr at 37 °C.  Cells treated with only psoralen were 
kept in HBSS for the same time as for the corresponding PUVA treatments. 
Immunofluorescent analysis was performed as described above using the 
flourochromes A4 FLUO (blue) for DAPI and GFP FLUO (green) for XPA. The 
images were acquired with a Leica DMI6000 microscope and objective lenses 
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(magnification/numerical aperture) HCPLAN APO 10X/0.03 or HCX PL 
FLUOTAR 20X/0.07. Dry imaging medium was used at room temperature. A 
Leica DFC360 FX camera captured the images and Leica Application Suite X 
(LAS X) 1.1.0.12420 1997-2014 version of software was used.  
 
2.2. Transactivation and NGS 
 
106 fibroblast cells were cultured 24 to 48 hr or until 90% confluent. 2 X 
106 cells were treated with either 10 µM all-trans retinoic acid (RA) or an equal 
volume of dimethyl sulfoxide (DMSO) for different periods. HeLa S3 were 
cultured in RPMI (Thermo Fisher Scientific) media with 10% FBS and 1% penici-
llin/streptomycin solution. HeLa cell lines were treated with 1 µM RA or an equal 
volume of DMSO. The final concentration of DMSO was 0.01% in the cell culture. 
The fibroblast cells were harvested with a cell scraper. Each sample was 
centrifuged and washed with phosphate buffer saline (PBS) once, centrifuging at 
1500 rpm (485 x g) for 5 min at 4 ºC. The pellets were quick-frozen and stored at 
-80 ºC. RNA was extracted from pellets using a QIAGEN RNA isolation kit for a 
qPCR assay. The qPCR data were analyzed for fold-change in mRNA level of 
the human RARB gene at different time points. A time point of maximum 
response was determined to prepare the samples for RNA-Seq analysis. Cells 
were treated as described above and cell pellets were submitted for Next 
Generation sequencing (NGS).  
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2.3. RNA Sequencing  
 
Sequencing: The libraries were prepared using the Illumina TruSeq stranded 
mRNA kit according to the manufacturer’s protocol, except that the number of 
PCR amplification cycles was reduced to 8. The libraries were loaded on cBot 
(Illumina, San Diego, CA) at a final concentration of 10 pM to perform cluster 
generation, followed by 2 x 76 bp paired end sequencing on a HiSeq 2500 
instrument (Illumina). A total of 48 libraries (three biological replicates per 
condition) were sequenced in 6 lanes, generating 16-41 million pairs of reads per 
sample. Each pair of reads represents a cDNA fragment from the library. 
 
Mapping: The reads were mapped to the human genome (hg19) using TopHat 
(version 2.0.10) (105).  The overall mapping rate of reads was 87-96%. 76-93% 
fragments, depending on the experiment, had both ends mapped to human 
genome. 
 
Differential Expression: The number of fragments in each gene from the 
RefSeq database (106) (downloaded from UCSC Genome Browser on July 17, 
2015) was enumerated using HTSeq-count from the HTSeq software package 
(version 0.6.0) (107). Genes with less than 10 fragments in all samples were 
removed before differential expression analysis. The differential expression 
between conditions was statistically assessed using the R/Bioconductor package 
DESeq (version 1.18.0, for DMSO vs. DMSO) (108) and edgeR (version 3.8.6, 
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for DMSO vs. RA) (109).  Differential expression of genes with FDR (false 
discovery rate) ≤ 0.05 was considered significant and a fold change (FC) ≥ 1.5 
was used for more rigorous analyses. 
 
2.4. Analysis of NGS data 
 
NGS data were curated to identify the significant (FDR 0.05) differentially 
expressed genes in XPA-proficient cells compared to their respective deficient 
cells, and genes with fold change levels >1.5. Gene set enrichment analysis, 
pathway analysis and statistical gene enrichment analysis were performed using 
Gene Ontology (GO) Consortium (110), Gene Set Enrichment Analysis (GSEA) 
(111) and QIAGEN’s IPA programs using GO as the data source. Bonferroni’s 
correction was used wherever possible when using GO consortium for pathway 
and gene enrichment or over-representation test analysis.  
 
2.5. Preparation of components needed to establish the NER dual incision 
control assay 
 
 2.5.1. M13mp18GTG single stranded DNA 
 
Single stranded circular DNA of M13 bacteriophage (Mp13m18GTG) was 
needed to make the double stranded circular DNA containing a cisplatin adduct, 
to use as substrate for nucleotide excision repair assays (102). M13mp18GTG 
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single stranded circular DNA from M13 bacteriophage was isolated by infecting a 
culture of E. coli strain JM109, with the bacteriophage, grown on M9 minimal 
selecting media supplemented with 0.1% thiamine. 0.5 ml of bacteriophage stock 
(1012 pfu/ml) was incubated at room temperature for 5 minutes in 2.5 ml of fresh 
culture of JM109. The mixture was added to 500 ml of Luria Broth (LB) with 5 
mM MgCl2 and incubated for 5 hr with vigorous shaking at 37 °C. The culture 
broth was centrifuged at 700 x g for 15 minutes to pellet the bacteriophage-
infected JM109. Replicative form (RF) of M13mp18GTG, which is a double 
stranded circular DNA, was extracted from the pellet. The phage from the 
supernatant was precipitated using polyethylene glycol (PEG) and the single 
stranded circular DNA was extracted by the phenol chloroform extraction 
method. Single stranded DNA was obtained with a concentration of 1.6-2 µg/µl. 
The purity of single and double stranded DNA was analyzed on 0.8% agarose 
gel run in presence of ethidium bromide at 20 mA for 5 hours (Figure 5). 
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0.8% agarose gel with ethidium bromide (40 µg/ 100 mL) run in Tris-Borate- 
EDTA (TBE) buffer with ethidium bromide at 20 mA for 5 hours. Single stranded 
(SSDNA) and double stranded (DSDNA) derived from M13 single stranded DNA 
are used as controls to confirm the newly purified single stranded DNA 
(M13mp18GTG) as indicated at the top of the gel.  
	    
M13$
SSDNA$
1ug$
$
$
$$ 
SSDNA$ DSDNA$
FIGURE 5. Single stranded and double stranded closed circular DNA 
derived from M13 bacteriophage 
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2.5.2. Whole cell extracts 
 
  Whole cell extracts of HeLa S3 and KO38 were prepared following 
Biggerstaff and Wood’s protocol (100, 112). A high protein concentration of about 
15-20 mg/ml is necessary for the repair assays to take place efficiently in vitro. 
The cell extracts are made from 109 cells in 2L or 3L cultures to assure a high 
protein concentration. The cells were pelleted and incubated in hypotonic lysis 
buffer for 30 min followed by homogenization. Protease inhibitors were added to 
inhibit proteolysis. Protein was precipitated and concentrated using sucrose-
glycerol buffer and ammonium sulfate in 4°C. High-speed centrifugation at 
213000 x g at 4°C for 3 hr was done to separate DNA and other impurities from 
protein. Supernatant was separated carefully and dialyzed for 8 hr and 2 hr in 
dialysis buffer consisting of 0.1 M KCl, 12 mM MgCl2, 1 mM EDTA, 17% glycerol, 
2 mM DTT and 25 mM HEPES at pH 7.8. The whole cell extracts were quick 
frozen and stored at -80°C in aliquots to avoid repeated freezing and thawing. 
 
2.5.3. Double stranded circular DNA with intrastrand cisplatin adduct 
 
  A primer containing a cisplatin adduct for synthesis of double stranded 
circular DNA was prepared as described (102). Platination of the 24-mer 
oligonucleotide (TCT TCT TCT GTG CAC TCT TCT TCT) was achieved by 
incubating a 3:1 molar ratio of oligonucleotide and cisplatin in platination buffer (3 
mM NaCl, 0.5 mM Na2HPO4 and 0.5 mM NaH2PO4) for 16 hr. The reaction 
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mixture was run on 20% polyacrylamide sequencing gel and gel-purified by the 
crush and soak method. In this method, an excised piece of gel is crushed and 
soaked in nuclease free water and incubated at 37 °C in a high-speed shaker 
(250 rpm). DNA is recovered from the water by removing the gel pieces and then 
concentrating DNA in a speed vacuum concentrator. To check if the DNA 
obtained was modified or unmodified, DNA samples obtained from the gel 
purification were radiolabeled with [γ-32P] deoxyadenosine triphosphates, run on 
a 20% polyacrylamide sequencing gel and exposed to X-ray film for 5 minutes. 
The unmodified and modified DNA was observed differing in migration by about 1 
nucleotide (Figure 6A). 
 
  The 24-mer oligonucleotide with a cisplatin adduct was used as primer to 
make double stranded circular DNA. The primer (100 µM) was annealed with 
single stranded circular DNA derived from M13 bacteriophage (25 µg) in NEB 
Buffer 2 in a thermocycler at 65 °C for 5 minutes and gradually cooled to 4°C 
over the period of 75 minutes. The complementary strand synthesis was done 
using annealed DNA with 8 µg/ml RB69gp43 DNA polymerase in a reaction 
mixture containing 3.75 µl NEB buffer 2, 5 mg/ml BSA, 2 mM ATP, 0.6 mM each 
dNTP and 30 units of T4 DNA ligase (NEB) in 50 µl volume was done at 37°C for 
3 hours. The double stranded DNA so formed was purified by mixing the DNA 
with cesium chloride and ethidium bromide and centrifuging for 24 hours at 
60,000 rpm in a Type Ti 70 rotor to create a density gradient of cesium chloride 
to separate pure double stranded DNA from nicked and linear DNA. The DNA 
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bands intercalated with ethidium bromide were identified under UVA light. Double 
stranded circular DNA was withdrawn with a syringe and purified from salts and 
other impurities by using Amicon 100K centriguation columns (EMD Millipore 
Inc.). The substrates were analyzed by restriction digestion with ApaLI enzyme. 
Cisplatinated double stranded DNA has a unique digestion site for ApaLI at the 
GTG site where cisplatin reacts with the DNA. The cisplatin containing DNA is 
resistant to ApaLI while ApaLI cuts the undamaged double stranded DNA (Figure 
6B). RB69gp43 was purified by Karen Boulware.  
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FIGURE 6. Verification of 1,3 GTG cisplatin primer and the cisplatin adduct 
in M13mp18GTG double stranded circular DNA. 
A. Denaturing 20% polyacrylamide with radiolabeled 24-mer oligonucleotides 
platinated (P), unplatinated (U) and 100 bp DNA ladder (L). B. 0.8% agarose gel 
with ethidium bromide run in TBE with ethidium buffer at 20 mM for 8 hours. The 
lanes consist of following samples; S: single stranded M13mp18GTG plasmid D: 
Double stranded M13mp18GTG.1 and 2: undamaged DNA, 3 and 4: cisplatin 
substrate. 1-4 are used in restriction digestion conditions with or without ApaLI. 
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2.6. DNA incision and repair assays with cisplatin intrastrand substrate 
 
2.6.1. NER dual incision control assay  
 
  Since it is well known that mammalian cells process cisplatin intrastrand 
crosslink adduct by NER dual incision (102), we established a control assay 
using cisplatin adduct in a circular plasmid. We prepared mammalian whole cell 
extracts and a single 1,3 (dGpTpG) cisplatin adduct substrate as described 
above and tested in NER dual incision assay using an end-labeling method as 
described by Moggs et al., 1996 (102). The 1,3 (dGpTpG) cisplatin substrate was 
incubated with mammalian whole cell extracts. Briefly, the reaction mixture 
consisted of 50 ng of Pt-GTG or control substrate, 40-45 µg of whole cell extract, 
in the NER buffer with a final concentration of 45 mM HEPES-KOH (pH 7.8), 70 
mM KCl, 7.5 mM MgCl2, 0.9 mM DTT, 0.4mM EDTA, 2 mM ATP, 2.5 µg of 
creatine phosphokinase, 3.4% glycerol and 18 µg of bovine serum albumin in a 
10 µl volume. The reaction is incubated at 30 °C for 5 min without DNA and 
incubated further for 30 minutes after DNA substrate was added and mixed. An 
oligonucleotide with a G-overhang at the 5’ end (GGG GGA AGA GTG CAC AGA 
AGA AGA GGC CTG GTC G) was added to the mixture and heated at 95 °C for 
5 minutes and cooled gradually at room temperature for 30 minutes. During this 
process, the G-overhang oligonucleotide was annealed to a complementary 
oligonucleotide excised by dual incision NER. Sequenase polymerase (0.13 U) 
was used to add [α-32P] deoxycytidine triphosphates opposite the G-overhang 
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using a final concentration of 2 µCi of [α-32P] dCTP and incubated at 37 °C for 3 
min followed by addition of 10 µM each of dATP, dTTP and dGTP, and 5 µM 
dCTP in the mixture and incubated for 12 more minutes. The reaction was 
stopped by adding 90% formamide with bromophenol blue dye and denatured by 
heating at 95 °C for 4 minutes. The reaction was run 40 cm on a denaturing 14% 
polyacrylamide gel or the sequencing gel at 50°C for about 2 hours or until the 
dye ran at the bottom of the gel. The gel was dried for 1-2 hr in gel drier and 
exposed to phosphoscreen for 1-2 days.  
 
2.6.2. Primer extension assay to a 1,3 (dGpTpG) cisplatin adduct 
 
A primer extension assay was performed in order to confirm the 1,3 
(dGpTpG) cisplatin adduct at a specific site of one strand of the closed circular 
double stranded DNA M13mp18GTGX. 25 pmoles of primer  
 (5’-CAGGAAACAGCTATGAC-3’) was radiolabeled with 17 pmoles of [γ-32P] 
ATP at its 5’ end by T4 Polynucleotide kinase (T4 PNK) in 1X T4 PNK buffer for 1 
hour at 37 °C. M13mp18GTGX was restriction digested by PvuI restriction 
enzyme at 37 °C for 1 hour, heat inactivated, purified by phenol-chloroform-
isoamyl alcohol and precipitated by 100% ethanol and 3M sodium acetate. 300 
ng of purified DNA was incubated with 20 fold more radiolabeled primer at 95 °C 
for 4 min, 48°C for 4 min and 37 °C for 1 min in the mixture of Sequenase V2.0 
polymerase (USB Inc.) 1.3 U, 1X Sequenase buffer and 80 µM dNTPs mixture, in 
a thermocycler. The amount of Sequenase V 2.0, a T7 DNA polymerase, which 
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lacks exonuclease activity, was titrated for efficient primer extension. As a control 
we used RB69gp43 polymerase, which had worked well in the past for primer 
extension of a 30 mer oligonucleotide with its specific primer. Sequenase V 2.0 
was found to be working well and we continued to use this polymerase for further 
primer extension assays. The reaction was stopped with 90% formamide buffer 
and heated at 95 °C for 4 minutes and run in a denaturing 14% polyacrylamide 
gel. The gel was dried in heated vacuum gel drier for 30 min to 2 hr. The dried 
gel was exposed to phosphoscreen for 1-2 days and scanned in GE Typhoon 
FLA 9500.  
 
2.6.3. DNA repair assay 
 
The DNA repair assay was done based on a DNA synthesis reaction as 
described in Moggs et al (102). DNA repair assay was performed in similar 
reaction conditions as NER dual incision assay in 50 µl volume and it included 
radiolabeled with [α-32P] dNTPs (20 mM of each dATP, dTTP, dCTP and dGTP, 
2 µCi of 3000 Ci/mmol). 300 ng of DNA was incubated in this reaction for 30 min 
at 30 °C after pre-incubating for 5 min without DNA. The repair intermediates 
were purified by phenol chloroform isoamyl extraction and ethanol precipitation 
as described earlier. The purified DNA is restriction digested with 15 units of 
BstN1 in 30 µl volume at 60 °C for 4 hours. The fragments were analysed by 
electrophoresis in a denaturing 14% polyacrylamide gel for 1.5 to 2 hr at 50 °C as 
described earlier.  
40 	  
 
2.7. Construction of TFO-directed psoralen ICL on a a closed circular 
double stranded DNA (psoralen-TFO ICL)   
 
2.7.1. Vector with BbsI ends 
 
 A pUC19 vector was mutated at T685A by using QuickChange Site-Directed 
Mutagenesis Kit (Stratagene), to mutate the Nt.BspQI site. A fragment was 
cloned into pCR4-TOPO TA cloning vector (Invitrogen). The mutation was 
confirmed by sequencing. The mutated plasmid was transformed into SCS110 
Competent Cells (Agilent Technologies) and colonies containing the mutated 
plasmid were selected for in LB broth with carbenicillin. DNA was extracted using 
a Wizard SV miniprep kit (Promega). Purified mutated-plasmid was restriction 
digested with XbaI and KpnI to remove the fragment and an insert consisting of a 
TFO binding site and BbsI restriction digestion sites at the ends was ligated with 
it. The purified ligated product was transformed in DH5-α cells. Colony PCR was 
done to confirm the insertion. Colonies with the correct insertion (result from 
PCR) were cultured in LB broth with carbenicillin and DNA was extracted. The 
sequences were confirmed for the whole plasmid. Thus this modified pUC19 
(pUC19N) consisted of two BbsI sites that brackets a TFO binding site together 
with 5’-AT-3’ site for crosslinking with psoralen (113).  
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   pUC19N (500 µg or more) was restriction digested with BbsI (2 Units/ µg 
DNA) at 37 ºC for 16-20 hours. DNA was purified by passing through DNA Clean 
& Concentrator centrifugation columns (Zymo Research), run in denaturing 6% 
polyacrylamide gel, stained with SYBR Safe (Invitrogen) for 30 min in dark. The 
gel was scanned in Typhoon 9500 at 532 nm. The vector bands were marked 
and excised with a clean razor blade. The bands were electroeluted in a dialysis 
bag in 0.5 X TBE buffer by running the gel at 200 V/cm for 45 minutes. DNA was 
precipitated from the electroeluate with 3 M sodium acetate pH 5.2 and ethanol 
at -20 ºC overnight, centrifuged at 20,000 x g at 4 ºC for 30 minutes, washed with 
2 volumes of 70% ethanol, air dried and resuspended in TE buffer pH 8.0. The 
concentration and the purity were measured on a NanoDrop 2000 (Thermo 
Scientific). 
 
2.7.2. 50 bp psoralen-TFO ICL  
 
Equal molarity of a 50 bp upper strand oligonucleotide  
(5’ Phos- 
CGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGC 
3’) 
and lower strand oligonucleotide (5’Phos- 
GCACGCGTCTTCGAGGGGGAGGGGGTGGTGGGGGGGGAAGGATGAAGAG
C 3’) were annealed together to form a duplex DNA, in TE buffer by heating at 95 
ºC for 2 minutes, and gradually letting it cool to room temperature for 3-4 hours 
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and stored at 4ºC. 50 fold more psoralen (4’ Hydroxymethyltrixosalen)-TFO (5’ 
HMT-C6-AGGAAGGGGGGGGTGGTGGGGGAGGGGGA-dGTP-NH2 3’) was 
incubated with 50 bp duplex DNA in 5X TBB (triplex binding buffer), which 
consisted of 10 mM MgCl2 and 10 mM Tris-Cl pH 7.6 for 16 hours at 37 ºC. The 
psoralen-TFO bound to DNA is exposed to UVA (365 nm) at 10 J/m2/s for 30 
minutes or 18 kJ/m2.  Small amounts of the UVA exposed products were 
confirmed for the interstrand crosslink by photo-reversal with UVC (0.7 kJ/m2), 
radiolabeled and run in a denaturing 6% polyacrylamide gel. The rest of the UVA-
exposed products were separated in a denaturing 6% polyacrylamide gel and 
stained with SYBR safe (Invitrogen). The interstrand crosslink bands were 
excised from the gel making sure not to contaminate them with any monoadducts 
or duplex DNA. The gel pieces were crushed in microfuge tubes and soaked in 
nuclease free water in a shaker at 37 ºC for 16-20 hours. The water separated 
from the gel pieces was collected and filtered through 0.22 µm pore cellulose 
centrifugation tubes (Corning® Coaster® SpinX®). It was kept at -80 ºC for 20 
minutes and concentrated in a vacuum centrifuge with 37 ºC heat until the 
volume reduced to 100-200 µl. The product was purified through a DNA Clean & 
Concentration column (Zymo-Research). The purity and the concentration of the 
insert were measured on a NanoDrop 2000. 
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2.7.3. Ligation reaction 
 
A small-scale ligation reaction was performed with 1:1.5, 1:3, and 1:5 ratio 
of vector to insert, 2 units of T4 DNA ligase, 1X T4 ligase buffer, 4 µg of BSA in a 
40 µl reaction volume at 16ºC for 2 hours in dark. The reaction was run in a 1% 
agarose gel with ethidium bromide. A 1:5 vector to insert reaction was chosen to 
scale up the reaction. A large-scale reaction was done in a 20 mL volume (500 
X). The reaction was concentrated in Amicon 30K 4 mL centrifugation tubes 
(EMD Millipore) at 3452 x g at 4 ºC until the volume was reduced to 1 mL. 
Further, the double stranded closed circular DNA was separated from nicked and 
single stranded DNA by cesium chloride / ethidium bromide gradient 
centrifugation. The double stranded circular DNA is collected from the lower 
band. The upper band consists of nicked and single stranded DNA. Ethidium 
bromide was removed by several extractions with water-saturated butanol and 
butanol is removed by centrifuging it several times with TE in Amicon 10K 4 mL 
centrifugation tube (EMD Millipore) at 4 ºC at 800 x g. The solution was 
concentrated to a final volume of 250-300 µl. 5X TBB was added to the purified 
DNA and incubated at 37 ºC for overnight and stored at 4 ºC. 
 
2.7.4. Confirmation of the ICL in the final product 
 
The final TFO-directed psoralen ICL on a closed circular double stranded 
DNA is referred here as psoralen-TFO ICL unless specified.  Small amounts of 
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the final ICL product (psoralen-TFO ICL) or pUC19N were restriction digested 
with BbsI for an hour at 37 ºC and run in a denaturing 6% polyacrylamide gel 
along with purified ICL insert, stained with SYBR gold for 30 min in the dark and 
scanned in the Typhoon 9500. The restriction digestion of psoralen-TFO ICL 
released a 50 bp ICL that runs similar to 50 bp ICL insert whereas the 50 bp 
fragment released from pUC19N runs as a normal 50 bp DNA. This confirms that 
the final product is TFO directed psoralen interstrand crosslink in closed circular 
double stranded DNA. 
 
2.7.5. Plasmid relaxation assay in whole cell extract 
 
500 ng of pUC19N was incubated for 5 minutes to 40 minutes in 100 µg of 
HeLa S3 whole cell extract protein or without whole cell extract in ATP 
regenerating buffer (NER buffer) as described in the NER incision reactions 
above. The reaction was stopped by using 20 mM EDTA and extracted using 
RNase, proteinase K, SDS and phenol-chloroform-isoamyl alcohol, and again 
with chloroform, precipitated with 100% ethanol and sodium acetate. The DNA 
pellet was obtained by high speed centrifugation at 4°C for 30 minutes, washed 
with 70% ethanol, air dried and dissolved in 20 µl of TE buffer. The samples were 
divided into halves and run in two 1% agarose gels with or ethidium bromide for 
either 20 mA for 8 hours or 80V for 2 hours. Pictures were taken in a Bio-Rad 
ChemiDoc imager.  
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2.8. DNA incision and repair assays with psoralen-TFO ICL 
 
2.8.1. Detection of 3’ incision on the upper and lower strand 
 
50 ng of pso-TFO ICL substrate was incubated in HeLa S3 whole cell 
extract in 50 µl reaction volumes in the buffer condition as described in the NER 
dual incision control assay. The reaction was stopped by adding 20 mM of EDTA 
and purified by equal volume of phenol-chloroform-isoamyl extraction and one 
more extraction with chloroform followed by precipitation of intermediate DNA 
products with absolute ethanol and sodium acetate by incubating at -20°C for 1 
hour. The precipitate was obtained by centrifugation at maximum speed in a 
table top centrifuge at 4°C for 30 minutes. The precipitate was washed with 70% 
ethanol, air-dried and dissolved in 10 µl TE buffer. The purified DNA products 
were restriction digested by 20 units of SbfI (NEB) enzyme for 2 hours at 37 °C 
and purified as before and dissolved in 10 µl of TE buffer. A G-overhang labelling 
oligonucleotide was designed to detect the incision products on the upper strand. 
6 ng of 3’ incision labelling oligonucleotide (5' 
GGGGTGCAGGTCGACTCTAGAGCGTCTTCG 3') was added and denatured at 
95 °C for 3 minutes and allowed to anneal with the incision products by gradually 
cooling at room temperature over 40 minutes. Incorporation of [α-32P]dCTP 
complementary to the G-overhangs on the labelling oligonucleotides was done 
as described in the NER dual incision control assay. Running the samples in the 
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sequencing gel and further processes were done as in the NER dual incision 
control assay.  
 
Another G-overhang oligonucleotide 
(5'GGGGGAGCACGCGTCTTCGAGGGGGAGGGGGT 3') was used to detect 
the incision products at the site within the TFO binding site following the method 
described above. For this detection process, the purified DNA product after 
incision reaction was restriction digested with 20 units of BfaI (NEB). Similarly to 
detect the incision products at the 3’ side on the lower strand, we used a G-
overhang oligonucleotide (5' GGGGGTACCGAAGACATCGATGCTCTTCAT 3').    
 
2.8.2. psoralen-TFO ICL repair assays 
 
Repair assays were performed to determine if the psoralen-TFO ICL could 
be repaired by human cell extract. The DNA repair synthesis reaction was based 
on that described by Moggs et al. (102) and purified as described for the DNA 
repair assay above. The purified DNA is restriction digested with 20 units of each 
SapI (NEB) and AluI (NEB) at 37 °C in 30 µl volume for 2 hr. The fragments are 
analysed by electrophoresis in a denaturing 14 % polyacrylamide gel for 1.5 to 2 
hr at 50 °C as described earlier.  
 
A similar repair synthesis assay was also performed where the purified 
DNA after the repair reaction was restriction digested by BbsI (NEB).  
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Chapter 3. Results - Consequences of XPA disruption in human cells 
 
3.1. Validation of pairs of XPA-deficient and proficient cell lines  
 
The purpose of this study was to determine the extent to which XPA 
expression status influences overall gene expression in cultured cells. We 
considered it important to use independent, genetically matched pairs of cell lines 
where one cell line was completely XPA-deficient, and the other was XPA-
proficient. Four pairs of cell lines were investigated. Figure 4A indicates the sites 
of XPA mutation and deletion in each of the cell lines. Two pairs include widely 
used and characterized XPA-deficient cell lines derived from human skin 
fibroblasts of individuals with xeroderma pigmentosum group A, XP2OS and 
XP12RO. These were compared to the same cell lines complemented with a 
plasmid expressing XPA cDNA (Table 1). In both cases, there is ample evidence 
that XPA expression fully corrects the UVC radiation sensitivity and NER defect 
in these fibroblasts. As another comparison pair of cell lines, two CRISPR-Cas9 
mediated XPA-disrupted HeLa S3 cell lines were generated (Figure 4B). We 
reasoned that if any XPA-associated gene expression changes were found in 
common across several cell lines, they would represent the most biologically 
significant consequences of XPA expression. 
 
 In three of the XPA mutant cell lines, XPA protein was undetectable by 
immunofluorescent staining of cells (Figure 7) or by immunoblotting of cell 
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extracts (Figure 8A, B). This is consistent with the known mRNA destabilizing 
mutations in XP2OS (114) and XP12RO (115) (Figure 4). The HeLa KO142 cells 
encoded an XPA protein with a a deletion of six amino acids (residues 9-14) near 
the N-terminus (Figure 4A and 4B). This, perhaps surprisingly, destabilizes XPA 
expression, reducing it to ~10% of the level in the HeLa cells (Figure 8A and 8B). 
The GTX103168 antibody recognizes the globular core domain of XPA and also 
detected a reduced level of XPA in HeLa KO142 cells (Figure 8B). The HeLa 
KO38 cells had a frameshift mutation causing early termination and complete 
loss of XPA protein. UV irradiation of paired cell lines confirmed the NER 
deficiency in the XPA mutant cell lines showing that there is a reduced level of 
NER in KO142 (Figure 9A). This is consistent with previous data showing that 
XPA levels are rate-limiting for NER when reduced sufficiently (116, 117). HeLa 
KO38 cell extracts were completely deficient in NER and could be complemented 
by XPA protein (Figure 9B). The common genetic origin of the paired cell lines 
was confirmed by short tandem repeat analysis (Table 1). KO38 was a complete 
knockout. UV irradiation of paired cell lines confirmed the NER deficiency in the 
XPA mutant cell lines showing that there is a reduced level of NER in KO142 
(Figure 9A). This is consistent with previous data showing that XPA levels are 
rate-limiting for NER when reduced sufficiently (118).  We also tested if XPA 
protein in KO142 is affected by proteosomal degradation and thus is observed as 
low expression. MG132 proteosome inhibitor was used in the cell cultures for 24 
hours and cells were subjected to immunoblotting. No difference was observed in 
XPA protein level in presence or absence of MG132 (Figure 10).  HeLa KO38 
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cell extracts were completely deficient in NER and could be complemented by 
XPA protein (Figure 9B).  
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TABLE 1. Short Tandem Repeat (STR) fingerprinting report of cell lines 
used in the study 
Color-coding is used to denote the XPA proficient cell lines with their deficient 
pairs. The scores for repeats of 8 STR fingerprinting markers are given in the 
table to show that the cell line pairs matched each other. A total of 14 markers 
were used for the STR fingerprinting. All had matching scores for the pairs of cell 
lines, showing that the pairs are isogenic. 
  
Sample 
Name AMEL CSF1PO D16S539 D18S51 D21S11 D3S1358 D5S818 D7S820 
XP12RO X,Y 12 9,11 13,22 30.2 15,16 11,12 12 
XPAXP12RO X,Y 12 9,11 13,22 30.2 15,16 11,12 12 
XP20S X 10,11 12 13,16 29,30 16 11 8,12 
XPAXP20S X 10,11 12 13,16 29,30 16 11 8,12 
KO142 X 9,10 9,10 16 27,28 15,18 11,12 8,12 
KO38 X 9,10 9,10 16 27,28 15,18 11,12 8,12 
HeLa S3 X 9,10 9,10 16 27,28 15,18 11,12 8,12 
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Immunofluorescence images using anti-XPA antibody (12F5) and DAPI showing 
the presence of XPA in all XPA-proficient cell lines and little or no XPA in the 
deficient cell lines. DAPI (blue) staining of nuclei included for reference. 
  
 
 
 
 
FIGURE 7. XPA expression in the cell lines used in this study. 
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FIGURE 8. XPA expression in the cell lines used in this study by 
immunoblotting. 
A. Immunoblot of the cell lines with anti-XPA antibodies CJ1 and GTX103168, 
and alpha-tubulin or XPF antibodies as loading controls. B. Quantification of the 
immunoblots for the HeLa S3 cell lines shown in (A). The blue bars represent the 
alpha-tubulin or XPF control. The red bars represent the anti-XPA antibody. 
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A. UVC clonogenic survival for XPA-disrupted cell lines KO38 and KO142 
compared to wild type HeLa S3. Each point on the survival curves represents the 
mean of 3 independent experiments. KO38 is more sensitive to UVC compared 
to HeLa S3. KO142 has more moderate sensitivity compared to HeLa S3. B. 
A.  
B.  
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FIGURE 9. UVC sensitivity and NER complementation in the cell lines used 
in this study. 
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NER complementation assay. KO38 whole cell extracts complemented with 
purified XPA protein to produce incision products. 45 µg 1,3-intrastrand 
d(GpTpG)-cisplatin substrate was incubated with 45 µg whole cell extract. 
Various amounts of purified XPA protein were added to KO38 extracts. NER 
activity is detected with 44 and 88 µg of purified XPA combined with KO38 
extracts. Incision products were observed as dark bands between 25 bp to 35 bp 
where complementation was successful (lanes 6 and 7), similar to the incision 
products with NER proficient HeLa S3 extract (lane 1). 
UVC sensitivity clonogenic assay was performed by Megan Lowery and Karen 
Boulware purified XPA for NER assay. 
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 Figure 10. Proteasome Inhibition assay 
Cells were treated with proteosome inhibitor (MG132) or DMSO for 24 hours. 
Cell lysates from the treated cells were immunoblotted to determine if expression 
of XPA in KO142 increases in absence of protoesomal degradation. No 
difference was observed with and without MG132. XPF was used as a loading 
control.  
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3.2. XPA is localized in the nucleus of cells and does not require UV 
irradiation for import 
 
 In order to have a direct role as a transcription factor, XPA would have to 
be present in the cell nucleus, where transcription takes place. Although XPA is 
localized in the nucleus under standard fixation conditions (Figure 7,11A), we 
were concerned about reports that XPA is normally resident in the cytoplasm, 
and is only recruited to nuclei following UV radiation exposure (89, 91). We note 
that in those studies, cells were first briefly exposed to wash buffers containing 
Triton X-100 detergent or the milder fixation agent methanol, or with 0.05% NP-
40 detergent. As shown in Figure 11A (top row), XPA is entirely resident in the 
nucleus as visualized after paraformaldehyde fixation. However, because XPA is 
a relatively small protein (31 kDa), it easily leaks out of nuclei into the cytoplasm 
after only a few seconds’ exposure to a buffer containing 0.05% NP-40 (Figure 
11A, third row). 
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A. Immunofluorescence (IF) staining with 12F5 antibody (green) and DAPI (blue). 
Cells in the top two panels were stained without exposure to buffer containing 
detergent. This shows that XPA is localized in the nuclei of complemented 
XPA/XP12RO cells and is absent in XP12RO cells, regardless of exposure to 
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FIGURE 11. XPA is a nuclear protein and is resistant to extraction from the 
nucleus during DNA repair. 
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UVC. The lower two panels show that brief exposure to a buffer containing 0.05 
% NP-40 causes leakage of XPA into the cytoplasm in untreated cells but not in 
cells exposed to 20 J/m2 UVC. B. Exposure of XPA/XP12RO cells to increasing 
doses of UVC (from 0 J/m² to 60 J/m²) restricts the leakage of XPA to the 
cytoplasm. C. XPA/XP12RO cells were exposed to psoralen alone or to psoralen 
and then UVA radiation (PUVA). The 2 hr sample received 54 kJ/m² (first dose 
18 kJ/m2, second dose 36 kJ/m2) and the 2.5 hr sample received 72 kJ/m² (first 
dose 18 kJ/m2, second dose 54 kJ/m2). All cells were exposed briefly to a buffer 
containing 0.05 % NP-40 before fixation for IF. XPA leaked to the cytoplasm in 
the cells exposed to psoralen alone, but not in the PUVA treated cells. D. 
Quantification showing the % of XPA/XP12RO cells with cytoplasmic XPA 
following PUVA treatment with increasing total doses of UVA and a constant 
concentration of psoralen. All cells were exposed briefly to a buffer containing 
0.05 % NP-40 before fixation for IF.  The orange bar shows XPA leakage in cells 
exposed only to psoralen, and the blue bar shows a reduction in leakage 
following DNA damage induction with increasing UVA doses. 
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Cells exposed to sufficient DNA damage retained XPA in the nucleus for 
at least 30 minutes even after a brief wash in buffer containing NP-40 detergent. 
A UVC radiation dose of 20 J/m2 was sufficient to retain all detectable XPA in the 
nucleus (Figure 11A, fourth row and Figure 11B). This result is consistent with 
previous observations that XPA remains chromatin-bound after UV irradiation, 
but is extractable from chromatin in non-damaged cells (119). Similarly, we found 
that photoactivated psoralen lesions could also immobilize XPA in the nucleus, 
even in cells washed with buffer containing NP-40 (Figure 11C). Consequently, 
previous observations suggesting nuclear import of XPA following UV radiation 
appear to have been misinterpreted (91). Instead, XPA is always present in 
nuclei. Fixation in the presence of detergent facilitates nuclear membrane 
permeabilization, and XPA leaks out readily; DNA damage in the nucleus 
temporarily restricts such leakage while XPA is engaged in repair. Other 
examples of misinterpretation of the subcellular localization of proteins arising 
from the presence of detergent have been noted previously (93, 94). 
 
3.3. Influence of XPA status on overall gene transcription 
 
  To analyze gene expression, RNA was extracted from a culture of 106 
actively growing cells of each pair, and used for next-generation RNA-Seq. To 
gauge reproducibility, three replicate cultures were grown independently for each 
cell line and RNA was extracted from cell pellets for analysis. With an overall 
mapping rate of 87-96%, about 14,000 genes were analyzed for each pair of cell 
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lines. With a False Discovery Rate (FDR) less than or equal to 0.05, a very high 
proportion of genes (~9000 for each pair) were initially identified as differentially 
expressed between paired XPA-proficient and deficient cell lines (Table 2).  
 
However, the expression patterns of these genes for the four pairs of cell 
lines were very distinct from one another. The ratio of gene expression was 
calculated for XPA+/XPA- for each cell pair; positive log 2 values were termed 
“high” and negative log 2 values were termed “low”. We determined the genes 
that were uniformly “high” or “low” for all four cell pairs. This narrowed the set to 
325 genes with expression that is uniformly influenced by XPA status at an FDR 
< 0.05 (Table 2). 
 
 This set of 325 genes has the same trend of high or low expression in all 
the XPA-proficient cell lines compared to their deficient counterparts (Figure 
12A). We used Gene Ontology (GO) consortium software to analyze the 
PANTHER pathways of these genes (Table 3). Only 32 of the 325 genes were 
assignable by this analysis with p-value less than 0.01, but they represented a 
diversity of biological functions (Figure 12B). Notably, a substantial number of 
pathways referred to neurological disorders including Alzheimer’s disease, 
Huntington’s disease and Parkinson disease.  
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Cell lines 
 Genes 
Analyzed 
FDR0.05  
(High + Low) 
FC1.5  
(High + Low) 
XP2OS vs. XPA/XP2OS 14117 9526 1721 + 2206  
XP12RO vs. 
XPA/XP12RO 13669 10283 2750 + 2625 
KO38 vs. HeLa S3 14564 9520 1769 + 1701 
KO142 vs. HeLa S3 13824 8364 1642 + 1422 
Common genes 12022 176 + 149 11 + 16 
 
TABLE 2. Summary of genes analyzed by high-throughput RNA sequencing 
(RNA-Seq) and significant XPA-related differences. 
The first column shows the number of genes analyzable by RNA-Seq for each 
XPA proficient / deficient cell pair. The second column shows the number of 
genes with differential expression at a False Discovery Rate (FDR) of 0.05. The 
ratio of gene expression was calculated for XPA-/XPA+ for each cell pair; positive 
ln 2 values are termed “high” and negative ln 2 values are termed “low”. The third 
column shows for each cell pair the number of “high” or “low” genes with fold 
change (FC) of 1.5 or more. 
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A. Heatmap of the 325 genes (Table 2) having the same expression pattern, 
either high (yellow) or low (blue) in XPA proficient compared to deficient cell 
lines, at a cut off level of FDR 0.05. Differential expression of mRNA was 
obtained from high throughput RNA-Seq data. Experiments for each cell line pair 
were performed in triplicate and are numbered on the top of the heatmap. The 
ratio of gene expression was calculated for XPA-/XPA+ for each cell pair; positive 
B	  
	  
FIGURE 12. XPA dependent change in gene expression pattern and 
biological pathways influenced by XPA status. 
5 Integrin signalling pathway (P00034)
5 Wnt signaling pathway (P00057)
5 CCKR signaling map (P06959)
4 Inflammation mediated by chemokine and cytokine signaling pathway (P00031)
4 PDGF signaling pathway (P00047)
4 Oxidative stress response (P00046)
4 Gonadotropin-releasing hormone receptor pathway (P06664)
3 Alzheimer disease-presenilin pathway (P00004)
3 Insulin/IGF pathway-protein kinase B signaling cascade (P00033)
3 T cell activation (P00053)
3 Endothelin signaling pathway (P00019)
3 p38 MAPK pathway (P05918)
2 Apoptosis signaling pathway (P00006)
2 Angiogenesis (P00005)
2 Interleukin signaling pathway (P00036)
2 Ubiquitin proteasome pathway (P00060)
2 Huntington disease (P00029)
2 p53 pathway (P00059)
2 EGF receptor signaling pathway (P00018)
2 Parkinson disease (P00049)
2 PI3 kinase pathway (P00048)
2 Cytoskeletal regulation by Rho GTPase (P00016)
2 Circadian clock system (P00015)
2 B cell activation (P00010)
Total unique genes = 32
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log 2 values are termed “high” and negative log 2 values are termed “low”. The 
most differentially over- or under- expressed genes are listed to the right. B. 
PANTHER pathway analysis was performed using Gene Ontology (GO) 
consortium software for the 325 genes shown in part A. Most genes were 
unassigned to a pathway by this analysis. The figure shows the pathway 
assignment for the subset of 32 genes that had two or more hits to a PANTHER 
pathway. The number of genes represented in each pathway is given before the 
name of the pathway with PANTHER pathway terms in parenthesis. Some genes 
were assigned to multiple pathway terms. The full data and assigned genes are 
given in Table 3.  
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Panther Pathways  
 XPA - vs. XPA+ 
  
 High   Low 
# of 
genes  
hits 
Integrin signalling pathway (P00034) 
BCAR1, 
PIK3R3, 
RRAS 
COL1A1, 
FLNB 
5 
Wnt signaling pathway (P00057) 
EDN1, 
FZD1 
PPP3CA, 
ITPR1, 
CHD1L 5 
CCKR signaling map (P06959) BCAR1 
PPP3CA, 
RPS6, 
ITPR1, 
PDK1 5 
Inflammation mediated by chemokine and 
cytokine signaling pathway (P00031) 
RRAS 
CAMK2D, 
ITPR1, 
PDK1 4 
PDGF signaling pathway (P00047) 
MKNK2, 
PIK3R3 
ITPR1, 
PDK1 4 
Oxidative stress response (P00046) MKNK2 
EEF2K, 
DUSP4, 4 
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DUSP1 
Gonadotropin-releasing hormone receptor 
pathway (P06664) 
LHX2 
PPP3CA, 
ITPR1, 
DUSP1 4 
Alzheimer disease-presenilin pathway 
(P00004) 
FZD1 
MMP17, 
LRP3 3 
Insulin/IGF pathway-protein kinase B 
signaling cascade (P00033) 
TSC1, 
PIK3R3 
PDK1 
3 
T cell activation (P00053) PIK3R3 
PPP3CA, 
ITPR1 3 
Endothelin signaling pathway (P00019) 
EDN1, 
PIK3R3 
ITPR1 
3 
p38 MAPK pathway (P05918) MKNK2 
EEF2K, 
DUSP1 3 
Apoptosis signaling pathway (P00006) 
RIPK1, 
TMBIM6 
  
2 
Angiogenesis (P00005) 
FZD1, 
PIK3R3 
  
2 
Interleukin signaling pathway (P00036) MKNK2 PDK1 2 
Ubiquitin proteasome pathway (P00060) PSMC3 UBE2L6 2 
Huntington disease (P00029) 
CAPN2, 
TUBB2A 
  
2 
p53 pathway (P00059) PIK3R3 PDK1 2 
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p53 pathway feedback loops 2 (P04398) PIK3R3 PDK1 2 
EGF receptor signaling pathway (P00018) RRAS PHLDB2 2 
Parkinson disease (P00049) PSMA4 UBE2L6 2 
PI3 kinase pathway (P00048) PIK3R3 PDK1 2 
Cytoskeletal regulation by Rho GTPase 
(P00016) 
TUBB2A, 
CFL1 
  
2 
Circadian clock system (P00015) 
PER2, 
PER3 
  
2 
B cell activation (P00010) PIK3R3 
PPP3CA, 
ITPR1 2 
Axon guidance mediated by netrin 
(P00009) 
PIK3R3   
1 
Ionotropic glutamate receptor pathway 
(P00037) 
  CAMK2D 
1 
De novo purine biosynthesis (P02738)   IMPDH2 1 
Coenzyme A biosynthesis (P02736) PPCDC   1 
Alpha adrenergic receptor signaling 
pathway (P00002) 
  ITPR1 
1 
Hypoxia response via HIF activation 
(P00030) 
PIK3R3   
1 
Nicotine pharmacodynamics pathway 
(P06587) 
PPP1CA   
1 
Ascorbate degradation (P02729)   RPE 1 
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Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
(P00027) 
  ITPR1 
1 
p53 pathway by glucose deprivation 
(P04397) 
TSC1   
1 
mRNA splicing (P00058) PRPF19   1 
Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
(P00026) 
  PHKA1 
1 
Vitamin D metabolism and pathway 
(P04396) 
RXRA   
1 
VEGF signaling pathway (P00056) PIK3R3   1 
Transcription regulation by bZIP 
transcription factor (P00055) 
TTF1   
1 
General transcription regulation (P00023) TTF1   1 
Ras Pathway (P04393)   PDK1 1 
General transcription by RNA polymerase I 
(P00022) 
TTF1   
1 
FGF signaling pathway (P00021) PPP4R1   1 
TGF-beta signaling pathway (P00052) RRAS   1 
FAS signaling pathway (P00020) LMNA   1 
Thiamin metabolism (P02780) ITPA   1 
Histidine biosynthesis (P02747)   AADAT 1 
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Histamine H1 receptor mediated signaling 
pathway (P04385) 
  ITPR1 
1 
Heme biosynthesis (P02746)   RSAD1 1 
Cadherin signaling pathway (P00012) FZD1   1 
Blood coagulation (P00011)   PROCR 1 
Dopamine receptor mediated signaling 
pathway (P05912) 
PPP1CA   
1 
Muscarinic acetylcholine receptor 1 and 3 
signaling pathway (P00042) 
  ITPR1 
1 
Formyltetrahydroformate biosynthesis 
(P02743) 
DHFR   
1 
Angiotensin II-stimulated signaling through 
G proteins and beta-arrestin (P05911) 
  ITPR1 
1 
Tetrahydrofolate biosynthesis (P02742) DHFR   1 
Metabotropic glutamate receptor group I 
pathway (P00041) 
  ITPR1 
1 
De novo pyrimidine ribonucleotides 
biosythesis (P02740) 
  CTPS2 
1 
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TABLE 3. Panther pathways created using Gene Ontology (GO) database 
for common genes with similar expression pattern at FDR0.05 in XPA- vs. 
XPA+ comparison in all four pairs of cell lines used in the study.  
The first column consists of the Panther pathways for common differentially 
expressed genes. Columns on the right consist of the common higher or lower 
expressed genes for each pathway, and the total number of gene hits observed 
for each pathway. The pathways for neurological functions are presented in bold.  
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GO terms for FC2 
genes overlaping 
with 'Mitochondria’ 
(A) 
or ‘Mitophagy’ (B) GO 
genes 
Fold enrichment 
 
KO142 vs. 
HeLa S3 
  
KO38 vs.  
HeLa S3 
  
XP12RO vs. 
XPA/XP12RO  
  
XP2OS vs. 
XPA/XP2OS  
  
A B A B A B A B 
response to 
mitochondrial 
depolarisation 
(GO:0098780) 
27.01  > 100 21.43  > 100 24.6  > 100 28.43  > 100 
mitophagy in response 
to mitochondrial 
depolarization 
(GO:0098779) 
27.01  > 100 21.43  > 100 24.6  > 100 28.43  > 100 
macromitophagy 
(GO:0000423) 
27.01  > 100 21.43  > 100 24.6  > 100 28.43  > 100 
mitophagy 
(GO:0000422) 
21.77  > 100 17.27  > 100 19.83 98.69 24.67  > 100 
mitochondrion 
disassembly 
(GO:0061726) 
21.77  > 100 17.27  > 100 19.83 98.69 24.67  > 100 
organelle disassembly 
(GO:1903008) 
19.48  > 100 15.45 95.33 17.74 88.3 22.08 94.61 
mitochondrion 
organization 
13.66 33.18 11.28 28.66 11.26 26.55 15.17 28.44 
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(GO:0007005) 
macroautophagy 
(GO:0016236) 
15.53 70.41 10.56 68.58 12.12 60.35 15.09 64.66 
autophagy 
(GO:0006914) 
12.43 52.83 8.45 48.02 8.96 42.26 12.07 45.28 
regulation of cellular 
protein localization 
(GO:1903827) 
8.66  - 8.09  - 6.57  - 6.83  - 
regulation of 
establishment of 
protein localization 
(GO:0070201) 
6.57  - 5.46  - 5.1  - 6.03 -  
regulation of cellular 
localization 
(GO:0060341) 
6.55  - 5.45  - 5.31  - 5.31  - 
regulation of 
establishment of 
protein localization to 
mitochondrion 
(GO:1903747) 
23.91  - 29.26  - 21.77  - 25.55  - 
regulation of 
mitochondrion 
organization 
(GO:0010821) 
19.11 
 - 
20.42  - 21.54 -  23.86  - 
xenophagy 
(GO:0098792)  - 
 > 100 
 - 
68.79 
 - 
86.48 
 - 
92.66 
regulation of immune  - 26.13  - 15.59  - 24.5  - 28 
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effector process 
(GO:0002697) 
single-organism 
organelle organization 
(GO:1902589)  - 
14.02 
 - 
12.11 
 - 
11.21 
 - 
12.02 
cellular response to 
stress (GO:0033554)  - 
12.09 
 - 
12.36 
 - 
10.36 
 - 
11.1 
 
TABLE 4. Gene Ontology (GO) terms for genes for ‘Mitophagy’ or 
‘Mitochondria’ overlapping with 2 fold or more changed (FC2) genes in 
XPA- vs. XPA+ comparison in all four cell lines. 
The first column consists of the GO terms related to ‘Mitochondria’ or ‘Mitophagy’ 
from GO database. In the table, ‘A’ represents ‘Mitochondria’ and ‘B’ represents 
‘Mitophagy’. Each column ‘A’ and ‘B’ shows the fold enrichment of FC2 genes for 
each cell line pairs in the GO terms listed in the first column.  
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Biological 
Functions 
  
Genes with 
FC >1.5  
  
Gene Name  
XP12RO 
vs. 
XPA/XPA
12RO 
XP2OS 
vs. 
XPA/XP
2OS 
KO38 
vs. 
HeLa 
S3 
 KO142 
vs. 
HeLa S3 
Fold 
Change 
 Fold 
Change 
 Fold 
Change 
 Fold 
Change 
Metabolism  AKR1C1 
Aldo-Keto 
Reductase Family 
1, Member C1 16 48 7 7.5 
Metabolism  AKR1C2 
Aldo-Keto 
Reductase Family 
1, Member C2 21 20 17 7.5 
Metabolism  TMPRSS15 
Transmembrane 
Protease, Serine 
15 12 14 2 955 
Unknown in 
normal cells MAGEA3 
Melanoma-
Associated Antigen 
3 16 11 4 52 
Metabolism  AKR1C3 
Aldo-Keto 
Reductase Family 
1, Member C3 4 6.9 1.9 2 
Mitochondrial 
function  
(ATP 
generation) NDUFA4L2 
NADH 
Dehydrogenase 
(Ubiquinone) 1 
Alpha 
Subcomplex, 4- 1.5 2.63 7.5 7 
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Like 2 
Immunity PELI2 
Pellino E3 
Ubiquitin Protein 
Ligase Family 
Member 2 1.7 2.6 1.5 5.5 
Neurological 
development WFDC21P 
WAP Four-
Disulfide Core 
Domain 21, 
Pseudogene 1.8 2.5 1.8 1.5 
Circadian 
entrainment HOMER2 
Homer, Neuronal 
Immediate Early 
Gene, 2 6.2 2 1.9 11 
Neural crest 
development LHX2 
LIM Homeobox 
Protein 2 9 1.9 1.9 1.4 
Auditory 
maintenance DFNB31 
Deafness, 
Autosomal 
Recessive 31 1.5 1.9 1.7 1.6 
GPCR 
pathway ROR2 
Receptor Tyrosine 
Kinase Like 
Orphan Receptor 2 -21 -1782 -6.5 -2 
Not clear SH3RF3 
SH3 Domain 
Containing Ring 
Finger 3 -2.4 -84.4 -1.6 -6.4 
Mitochondrial 
organization CHCHD10 
Coiled-Coil-Helix-
Coiled-Coil-Helix 
Domain Containing 
10 -9.8 -42 -1.5 -1.7 
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Actin binding CORO6 Coronin 6  -1.5 -32 -1.7 -1.7 
Calcium ion 
binding RCN3 Reticulocalbin 3 -3.2 -21 -1.5 -1.5 
Negative 
regulation of 
myoblast PPAPDC3 
Phospholipid 
Phosphatase 7 -274 -16 -3 -3.6 
Negative 
regulation of 
MAPK DUSP4 
Dual Specificity 
Phosphatase 4 -4.3 -6.5 -1.5 -4 
Not clear FCHSD1 
FCH And Double 
SH3 Domains 1 -2.5 -3.5 -1.7 -1.5 
Collagen  COL1A1 
Collagen Type I 
Alpha 1 -1.5 -2.5 -1.5 -2 
Not clear GGT1 
Gamma-
Glutamyltransferas
e 1 -1.9 -1.6 -1.4 -1.9 
TNF pathway TBKBP1 
TBK1 Binding 
Protein 1 -3.7 -1.6 -2.1 -2.1 
Not clear SYNGR1 Synaptogyrin 1 -1.9 -1.6 -2 -2.5 
Matrix 
metalloprotea
se activity MMP17 
Matrix 
Metallopeptidase 
17 -1.7 -1.6 -9 -2.3 
Breast cancer  BCAS4 
Breast Carcinoma 
Amplified 
Sequence 4  -2 -1.5 -2.8 -2 
Platelate 
activation PROCR Protein C Receptor -2 -1.5 -3.4 -1.5 
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Cytoskeleton PHLDB2 
Pleckstrin 
Homology Like 
Domain Family B 
Member 2 -1.5 -1.5 -1.5 -1.5 
 
Table 5. Common genes that are the most differentially expressed in all 
four pairs of cell lines. 
Table includes the major biological functions in the first column for the gene list 
given in the second column. The names of the genes are given in the third 
column. The left four columns are the fold change of the differential expression in 
four pairs of cell lines in XPA- vs. XPA+ comparison. The positive fold change 
indicates the higher expression whereas the negative fold change indicates the 
lower expression in XPA+ compared to XPA-. Genes with positive fold change 
are given in bold letters. 
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3.4. XPA status influences expression of genes affecting mitochondria and 
mitophagy 
 
 Because XPA status has been reported to affect mitochondrial function 
and mitophagy, we examined gene expression specifically in relevant pathways. 
To narrow down the analysis, we focused on genes with a fold change (FC) of 
1.5 or more in each pair of cell lines (Table 2). Genes listed on the GO 
consortium for ‘mitophagy’ or ‘mitochondria’ were overlapped with FC2 genes 
from our experiment. Significantly, the FC2 genes with XPA-dependent changes 
common to all four cell lines were highly enriched for GO terms related to 
mitophagy or mitochondria (Table 4). This confirms and extends the evidence for 
an influence of XPA status on gene expression affecting mitochondrial 
maintenance and regulation of mitophagy.  
 
3.5. Classification of the most differentially expressed genes common 
among all cell pairs 
 
 To determine which genes have expression most reproducibly affected by 
XPA status, we began with the group with at least a 1.5 fold change (FC1.5) in 
each cell pair. The overlaps in the gene list between these four sets were 
determined. This narrowed the set to only 27 genes that were differentially 
expressed at FC1.5 and have a uniform trend of high or low expression among 
all four pairs of cell lines (Table 5). Among the most differentially expressed 
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genes were AKR1C1, AKR1C2, and AKR1C3. These genes are adjacent on 
human chromosome 10p15-p14 and encode (Figure 13) members of the 
aldo/keto reductase superfamily, discussed further below. There were other AKR 
family genes also close to these three genes (AKR1E2 and AKR1C4), which 
were not differentially expressed in XPA- vs. XPA+ analysis. It is possible that 
there are common regulatory factors for these three genes. Another gene more 
highly expressed in XPA+ cells was NDUFA4L2, which encodes a subunit of an 
NADH dehydrogenase localized in the mitochondria and important for ATP 
generation. Other significant “high” genes were WFDC21P, HOMER2, LHX2 and 
DFNB31, which have neurological functions (Table 5).  
 
We analyzed the AKR1C proteins in the cell pairs by immunoblotting. Both 
AKR1C1 and AKR1C2 protein levels were significantly lower in all XPA- cells 
compared to XPA+ cells (Figure14A and 14B). AKR1C3 protein levels were 
slightly higher in HeLa S3 than in the XPA mutants, and absent in some of the 
fibroblast XPA- and XPA+ cell lines (Figure 14B).  
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FIGURE 13. Location of AKR1C1, AKR1C2 and AKR1C3 on human 
chromosome 10. 
 
AKR1C1, AKR1C2 and AKR1C3 are located adjacent to one another and with 
other AKR family genes; AKR1E2 and AKR1C4. AKR1C1 and AKR1C3 have 
same direction of expression whereas AKR1C2 has opposite direction. Histone 
modifications indicate there may be common regulatory factors for AKR1C1, 
AKR1C2 and AKR1C3 genes. Different length of the genes represents different 
variants.  
The figure is adapted from the UCSC Genome Browser on Human (Dec. 2013 
hg38 Assembly) or Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, 
Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res. 
2002 Jun;12 (6):996-1006. 
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A. Immunoblot for the most differentially high expressed genes (AKR1C1, 
AKR1C2 and AKR1C3) in XPA proficient compared to deficient cell lines. 
AKR1C1 and AKR1C2 protein levels were lower in XPA deficient cells compared 
to proficient cells whereas AKR1C3 protein level was inconclusive.  B. 
Quantification of band intensity of AKR1C1 (red) and AKR1C2 (orange) and XPF 
(blue) as loading control.  
B. 
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FIGURE 14. Analysis of the most drastically changed gene expressions in 
XPA proficient compared to the deficient cell lines. 
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 KO38 
vs. 
HeLa 
S3 
KO142 vs. 
HeLa S3  
common 
in both 
HeLa 
pairs 
XP2OS vs. 
XPA/XP2OS 
XP12RO vs. 
XPA/XP12RO 
common in 
both fibroblast 
pairs 
High 1311 1184 458 1380 2409 341 
Low 1355 1076 346 1744 2163 462 
Total 2666 2260 804 3124 4572 803 
 
TABLE 6. More commonalities when fibroblasts and HeLa cells are 
considered independently. 
Number of genes with FC1.5 or more in XPA- vs. XPA+ comparison in fibroblast 
cell lines or HeLa cell lines shows more common high or low expression patterns 
compared to commonality among all four cell lines.  
  
83 	  
3.6. More commonalities within fibroblast and HeLa cell pairs 
 
 We also analyzed the data to compare the two skin fibroblast pairs to one 
another (XP12RO and XP2OS) and the two sets of data derived from HeLa cell 
(KO38 pair and KO142 pair). Within these pairs, there were many more genes in 
common that were differentially expressed in an XPA-dependent manner (Table 
6).  For FC1.5 genes, 803 (341 high + 462 low) genes in fibroblast cell lines and 
804 (458 high + 346 low) genes in HeLa knockout cell lines had a similar 
expression pattern, in contrast to the only 27 genes common between all four cell 
lines at this expression level. These genes were overrepresented for pathways 
similar to those observed with all four pairs of cell lines with more number of 
genes (Table 7) and some pathways with less number of genes and are different 
in fibroblasts and HeLa are listed in Table 8. 
 
3.7. Retinoic acid transactivation affects XPA-dependent transcription 
related functions 
 
  Because retinoic acid transactivation of some genes has been shown to 
depend on NER components in some instances, we treated cell pairs with all-
trans retinoic acid (RA) or a DMSO control.  Quantitative PCR was used to 
assess the response of retinoic acid treatment to the cell lines. All cell lines, both 
XPA-proficient and deficient, responded to RA as shown by an increase in the 
mRNA level of RARB, a direct target gene of RA (Figure 15A). HeLa cell lines 
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had the lowest transcriptional response of RARB. RNA-sequencing data from 
cells treated with retinoic acid or DMSO for 7 hr were analyzed for biological 
functions by Ingenuity Pathway Analysis (IPA). IPA analysis was done for the 
significantly differentially expressed genes (FDR0.05) for DMSO vs. RA, for 
genes with higher expression in XPA-proficient cell lines compared to their 
respective XPA-deficient cell lines. This showed that the XPA-dependent RA 
response is enriched for transcription related biological functions (Figure 15B). 
Transcription related functions had the highest rank on the list of the –log (p-
value) compared to other biological functions. Thus for retinoic acid 
transactivation, XPA proficiency might be functionally important. However, we 
found no common gene expression pattern among all four pairs of cell lines. 
There were 18 common genes that were FC1.5 or more changed within RA 
treated HeLa S3 compared to KO38 or KO142. However, no common genes 
were found in skin fibroblasts in similar conditions. As each cell line responded to 
retinoic acid treatment in a different manner, it appears that the gene expression 
changes are also different in different cell lines. Nevertheless, although specific 
gene expression patterns were different in all four sets of cell lines, common 
biological functions were represented by the gene expression changes in each 
pair of cell lines, with transcriptional functions at the top of the list (Figure 15B).  
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PANTHER pathways GO term 
XPA - vs. XPA+ 
# gene hits in 
HeLa cells 
# of gene hits 
in Fibroblasts 
Wnt signaling pathway  (P00057) 21 9 
Huntington disease  (P00029) 14 6 
Cadherin signaling pathway (P00012) 14 9 
Integrin signaling pathway  (P00034) 13 12 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway (P00031) 13 8 
CCKR signaling map (P06959) 12 9 
Gonadotropin-releasing 
hormone receptor pathway  (P06664) 11 17 
PDGF signaling pathway  (P00047) 10 6 
EGF receptor signaling 
pathway  (P00018) 10 10 
Angiogenesis (P00005) 9 7 
Alzheimer disease-presenilin 
pathway (P00004) 9 10 
Nicotinic acetylcholine 
receptor signaling pathway  (P00044) 9 2 
Cytoskeletal regulation by (P00016) 9 3 
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Rho GTPase  
Apoptosis signaling pathway  (P00006) 7 4 
Parkinson disease  (P00049) 7 2 
Interleukin signaling pathway  (P00036) 7 6 
FGF signaling pathway (P00021) 7 6 
Blood coagulation (P00011) 7 2 
Heterotrimeric G-protein 
signaling pathway-Gi alpha 
and Gs alpha mediated 
pathway (P00026) 6 11 
Endothelin signaling pathway  (P00019) 6 7 
Alzheimer disease-amyloid 
secretase pathway  (P00003) 5 5 
p53 pathway  (P00059) 5 4 
T cell activation  (P00053) 5 3 
TGF-beta signaling pathway  (P00052) 5 7 
Oxidative stress response  (P00046) 5 5 
Hypoxia response via HIF 
activation  (P00030) 4 1 
Ras Pathway (P04393) 4 6 
Heterotrimeric G-protein 
signaling pathway-Gq alpha 
and Go alpha mediated (P00027) 4 6 
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pathway  
B cell activation  (P00010) 4 3 
5HT2 type receptor mediated 
signaling pathway (P04374) 4 1 
Axon guidance mediated by 
netrin  (P00009) 3 1 
VEGF signaling pathway  (P00056) 3 3 
PI3 kinase pathway  (P00048) 3 1 
Insulin/IGF pathway-protein 
kinase B signaling cascade (P00033) 3 1 
Oxytocin receptor mediated 
signaling pathway  (P04391) 3 1 
p38 MAPK pathway  (P05918) 3 2 
Toll receptor signaling 
pathway (P00054) 2 6 
Notch signaling pathway  (P00045) 2 3 
5HT1 type receptor mediated 
signaling pathway (P04373) 2 3 
Muscarinic acetylcholine 
receptor 2 and 4 signaling 
pathway  (P00043) 1 3 
Opioid proopiomelanocortin 
pathway  (P05917) 1 3 
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TABLE 7. Cell specific analysis of biological pathways with more number of 
genes represented in each pathway compared to analysis with all cell lines. 
PANTHER pathways significantly represented by common differentially 
expressed genes (FC=>1.5) in XPA proficient cells compared to XPA deficient 
cells among HeLa cells or fibroblast cells. Table consists of the list of the 
pathways that are common in both among HeLa cells (KO38 vs. HeLa S3 and 
KO142 vs. HeLa S3) and fibroblasts (XP12RO vs. XPA/XP12RO and XP2OS vs. 
XPA/XP2OS) excluding the pathways that consists of only one or two genes in 
both groups. 
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PANTHER pathways GO term 
XPA- vs. XPA+ 
# Gene hits in 
Fibroblasts  
# Gene hits 
in HeLa cells  
GABA-B receptor II signaling  (P05731) 4 0 
Opioid prodynorphin pathway  (P05916) 3 0 
FAS signaling pathway  (P00020) 3 0 
Alpha adrenergic receptor 
signaling pathway  (P00002) 2 0 
Enkephalin release  (P05913) 2 0 
Beta3 adrenergic receptor 
signaling pathway  (P04379) 2 0 
5-Hydroxytryptamine degradation  (P04372) 2 0 
Axon guidance mediated by 
semaphorins  (P00007) 1 0 
O-antigen biosynthesis  (P02757) 1 0 
N-acetylglucosamine metabolism  (P02756) 1 0 
Adrenaline and noradrenaline 
biosynthesis  (P00001) 1 0 
Methionine biosynthesis  (P02753) 1 0 
Lipoate_biosynthesis (P02750) 1 0 
Glutamine glutamate conversion  (P02745) 1 0 
Coenzyme A biosynthesis  (P02736) 1 0 
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Synaptic vesicle trafficking  (P05734) 1 0 
Endogenous cannabinoid 
signaling  (P05730) 1 0 
Histamine H2 receptor mediated 
signaling pathway  (P04386) 1 0 
Corticotrophin releasing factor 
receptor signaling pathway  (P04380) 1 0 
Proline biosynthesis  (P02768) 1 0 
Glycolysis  (P00024) 0 3 
Pentose phosphate pathway  (P02762) 0 3 
mRNA splicing  (P00058) 0 2 
Transcription regulation by bZIP 
transcription factor  (P00055) 0 2 
Nicotine pharmacodynamics 
pathway (P06587) 0 2 
Salvage pyrimidine 
ribonucleotides (P02775) 0 2 
Cell cycle  (P00013) 0 2 
Androgen/estrogen/progesterone 
biosynthesis  (P02727) 0 1 
JAK/STAT signaling pathway (P00038) 0 1 
Interferon-gamma signaling 
pathway  (P00035) 0 1 
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p53 pathway by glucose 
deprivation (P04397) 0 1 
Heterotrimeric G-protein signaling 
pathway-rod outer segment 
phototransduction  (P00028) 0 1 
General transcription by RNA 
polymerase I  (P00022) 0 1 
Salvage pyrimidine 
deoxyribonucleotides  (P02774) 0 1 
Angiotensin II-stimulated signaling 
through G proteins and beta-
arrestin  (P05911) 0 1 
Histamine H1 receptor mediated 
signaling pathway  (P04385) 0 1 
Pyrimidine Metabolism  (P02771) 0 1 
Purine metabolism (P02769) 0 1 
 
TABLE 8. Cell specific analysis of biological pathways showing difference 
in HeLa and fibroblasts. 
PANTHER pathways significantly represented by common differentially 
expressed genes (FC=>1.5) in XPA proficient cells compared to XPA deficient 
cells among HeLa cells or fibroblast cells. Table consists of the list of the 
pathways that are different in in HeLa cells (KO38 vs. HeLa S3 and KO142 vs. 
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HeLa S3) and fibroblasts (XP12RO vs. XPA/XP12RO and XP2OS vs. 
XPA/XP2OS).  
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FIGURE 15. Retinoic acid transactivation affects XPA-dependent 
transcription related functions. 
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A. qPCR results for all the XPA proficient and deficient cell lines showing 
responses to RA treatment at 7 hours. RARB gene expression was analyzed for 
RA or DMSO treated cell lines. GAPDH was used as control. The mRNA of 
RARB in RA treated condition was normalized to the DMSO- only controls. B. 
IPA analysis comparing the RA treated to untreated cells. Genes that were 
differentially expressed at FDR0.05. XPA proficient cell lines (red) compared to 
the XPA deficient cell lines (black) were analyzed. The scores are presented as 
negative log values of p-values, showing that XPA+ cells have higher significant 
differences than in XPA- cells, comparing the response to RA treatment with 
control treatment for a given function shown on the x-axis.  
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Chapter 4. Results - Processing of a TFO-directed interstrand crosslink in 
human cell extracts 
 
 ICL causing agents are used in chemotherapies to kill cancer cells but the 
exact mechanism for the processing DNA ICLs in human cells is not known. This 
project explored the mechanism of processing DNA-ICLs in human cells. For this 
purpose we first established a control NER dual incision assay with a 1,3 
d[GpTpG] cisplatin intrastrand crosslink built into a closed circular double 
stranded M13mp18GTGX DNA (102). The substrate was confirmed, and cell 
extracts and the reaction conditions were established to show the control assay 
works well for the incision and repair assays. To map out the incision sites on the 
psoralen-TFO ICL substrate we constructed a site-specific psoralen ICL in a 
closed circular DNA with a psoralen conjugated to a TFO. We used this substrate 
in the incision and repair assays to study the processing in human cell extracts.  
 
4.1. Validation of the cisplatin intrastrand substrate by primer extension 
assay 
 
 The purified cisplatin intrastrand crosslink was used in a primer extension 
assay to detect blockage of the extension of DNA polymerase. The lesion 
successfully blocked the extension process of the Sequenase polymerase 
(Figure 16). A PvuI restriction digested fragment encompasses the cisplatin 
intrastrand adduct. The fragment is 201 bp long with a primer-annealing site at 
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one end. The adduct is 39 nucleotides away from the 5’ end of the primer. As 
expected, we observed that the restriction digested fragment extended to 201 bp 
when no adduct is present and the adduct-obstructed fragment extended to only 
39 bp, confirming the presence of the cisplatin adduct at the specific site.  
 
 We used two kinds of controls. One is the replicative form of the M13 
single stranded plasmid, which is a double stranded circular DNA. The other 
control plasmid was made similar to the cisplatin-damaged plasmid, except an 
unplatinated oligonucleotide was used instead of cisplatin containing 
oligonucleotide. In both controls there was full extension of the radiolabelled 
primer to 201 bp. Some extended 201 bp fragments were also observed with 
damaged plasmid. This may be due the presence of small amount of 
unplatinated plasmid.  
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This fragment is 201 bp long. Denaturing 14 % polyacrylamide gel showing  
control (con) and replicative form of M13mp18GTG (RF) extended to 201 bp and 
cisplatin substrate (Pt) blocked by the adduct at 39 bp. 
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FIGURE 16. Primer extension assay using a fragment of M13mp18GTGX 
from the 5’ end of the radiolabelled primer to the 3’ end cut by PvuI enzyme. 
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4.2. NER dual incision control assay was established 
 
4.2.1. Major incision products and minor incision products were observed 
as shown by previous studies 
 
A 1,3d[GpTpG] cisplatin intrastrand crosslink built into a closed circular 
double strand M13mp18GTGX DNA has been shown to be processed by human 
cell extracts in NER dependent dual incision (102). It has been reported that 
human cell extracts make major incisions between the 8th and 9th nucleotide at 
the 3’ side and between the 15th and 16th nucleotide at the 5’ side, resulting in the 
major incision products of this cisplatin adducts in human cells of 27-32 
nucleotide long (102). This substrate was used as a control for the psoralen 
interstrand crosslink substrate. Using the similar conditions of reactions that were 
used in Moggs et al, 1998 (102), we performed a dual incision assay and 
mapped the incision product by using the G-overhang oligonucleotide labelling 
method. We successfully detected incision products that were produced due to 
dual incision on either side of the cisplatin adduct using human cell extracts. The 
incision products produced were between 25 to 35 nucleotides long (Figure 17). 
The major incision products were observed between 27-29 nucleotides long. The 
dual incision result in Mogg’s et al, 1998 (102), where the incisions were 15 
nucleotides away from the adduct at the 5’ side and 9 nucleotides away from the 
adduct on the 3’ side was reproduced in our dual incision assay. This result 
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confirmed that the cell extract, the DNA substrate, and the reaction conditions we 
used are all functional for the incision reactions.   
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FIGURE 17. NER dual incision control-assay. 
A. Detection of incision products by the G-overhang end labeling method, which 
adds 4 nt to the primary incision product length as described in the Chapter 2. B. 
Denaturing 14% polyacrylamide sequencing gel with major and minor incision 
products plus 4 radiolabelled CTPs, indicated by long and short arrows 
respectively, from NER dual incision control assay. The major labeled products of 
30, 33 and 34 nt correspond to the major primary incision products of 26, 29 and 
30 nt as observed previously (102). 
  
A. B. 
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4.2.2. A 1,3 d[GpTpG]  cisplatin intrastrand crosslink is repaired by HeLa 
whole cell extract as observed by previous studies 
 
We wanted to confirm that the reaction conditions that we have 
established can be used for repair synthesis with the cisplatin substrate, as it is 
known that this substrate can be repaired well in human cell extracts provided 
with the supply of necessary dNTPs. We performed the repair synthesis assay 
with similar reaction conditions as in the Moggs et al., 1996 paper (102). HeLa 
S3 cell extracts can repair the cisplatin substrate by filling the gap created by 
dual incision with radiolabelled dNTPs. Then, the plasmid was digested with 
BstN1, which creates 8 different size fragments in M13mp18GTGX DNA, among 
which a 33 bp fragment is where the repair synthesis occurs. We observed this 
fragment with the highest intensity by autoradiography (Figure 18). Some 
neighbouring fragments were also labelled. These fragments were fainter than 33 
bp fragments indicating that the more radiolabelled dNTPs preferentially were 
incorporated into the 33 bp region. This result suggests that the repair process 
has occurred, which assured us that we could use this assay to study the repair 
of TFO-directed ICL substrate.  
 
4.2.3. Incisions on the 1,3 d[GpTpG] cisplatin intrastrand crosslink were 
dependent on NER protein  
 
Dual incision of the cisplatin substrate is mediated by NER (102). An XPA 
deficient HeLa S3 (KO38) was made by CRISPR-Cas9 technology. We prepared 
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the KO38 whole cell extracts and used purified XPA protein to complement the 
deficiency in the dual incision assay. We observed the similar dual incision 
products as with XPA proficient HeLa S3 whole cell extract in the complemented 
assay. No products were detected in KO38 whole cell extract without 
complementation, showing that the incisions are dependent on NER. The result 
is presented in Section 3.1 and Figure 9B.  
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FIGURE 18. Repair synthesis assay.   
A. Denaturing 14% polyacrylamide gel showing BstN1 digested fragments of 
cisplatin and control substrate after repair synthesis. A 33 bp long band 
encompassing the cisplatin substrate was most intense compared to the control, 
showing incorporation of radiolabelled dNTPs at the repair site. B. Schematic 
diagram of restriction digestion sites around cisplatin adduct. 
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4.3. TFO-directed Psoralen interstrand crosslink was constructed and 
purified 
 
The TFO –directed psoralen interstrand crosslink in a closed circular 
double stranded DNA was constructed, purified and used as an ICL substrate in 
the experiments to determine how it is processed by mammalian cells. 
Construction of pure and high yield ICL substrate has been difficult task for ICL 
repair studies. The 50 bp short duplex TFO-directed psoralen ICL substrate was 
made using technology and reagents developed by Dr. Karen Vasquez’s 
laboratory (25). Then we developed the methodology to construct TFO- directed 
psoralen ICL in closed circular DNA (Figure 19, see methods in Chapter 2 for 
details). Confirmation of the components of the TFO-psoralen ICL is presented in 
the following sections.   
 
4.3.1. 50 bp psoralen-TFO ICL insert was constructed and purified 
 
A 50 bp TFO-directed psoralen ICL migrates slowly on a denaturing 6% 
polyacrylamide gel because it represents two strands linked together with a 
triplex forming oligonucleotide and psoralen. We observed the psoralen-TFO ICL 
at around the 150 bp (Figure 20). After purifying the UVA mediated psoralen-TFO 
ICL in the 50 bp duplex DNA, we confirmed the presence of interstrand crosslink, 
by using UVC photoreversal. UVC exposed ICL sample was observed to reverse 
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back to monoadduct and linear 50 bp DNA (Figure 20). This is the confirmation of 
the formation of the ICL.  
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pUC19 plasmid was modified to include a BbsI restriction digestion site. pUC19N 
plasmid was constructed and purified. By restriction digestion with BbsI enzyme, 
vector was created and purified. A 50 bp duplex DNA was annealed with TFO 
conjugated with HMT psoralen at its 5’ end and was crosslinked by UVA 
photoactivation to make ICL insert. The vector and insert were ligated in 
appropriate condition to get a circular double stranded DNA with psoralen-TFO 
ICL. 
  
BbsIBbsI
BbsIBbsI
BbsIBbsI
Add TFO-psoralen ICL Purify
Restriction digest Ligate and purify 
pUC19N psoTFOpUC19ICL
FIGURE 19. Strategy for the construction of TFO- directed psoralen ICL in 
closed circular double stranded DNA. 
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 A. Process of making a TFO-directed psoralen on a short duplex DNA. B. 6% 
polyacrylamide gel showing the formation of the ICL, monoadduct, and remaining 
duplex DNA. The conversion of ICL to monoadduct and duplex DNA by UVC 
photoreversal is the confirmation of ICL formation as shown in the right lane. The 
nucleotide make-up of the psoralen-TFO ICL is shown in the inset. Green 
represents the nucleotides of TFO binding site. The third strand is the TFO 
bound to the first two strands (duplex DNA) with Hoogsteen hydrogen bonding 
represented by the asterisk (*). Gray dots represent Watson and Crick hydrogen 
bonding. 
A. 
5’ CGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGC 3’ 
    3’ CGAGAAGTAGGAAGGGGGGGGTGGTGGGGGAGGGGGAGCTTCTGCGCACG 5’ 
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FIGURE 20. 50 bp TFO directed psoralen ICL. 
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4.3.2. Vector with BbsI sites was prepared 
 
BbsI restriction digestion sites were inserted into the pUC19N plasmid. 
BbsI has unique sequences at both 5’ side and 3’ side which reduces the 
chances of defective ligation. After purifying modified pUC19N, we tested if the 
BbsI site is incorporated at the correct site in pUC19N plasmid by running the 
BbsI digested sample on denaturing 6% polyacrylamide gel (Figure 21). A 50 bp 
band was released from the pUC19N plasmid. The remaining linear pUC19N 
was observed near the well.  
 
4.3.3. Vector and psoralen-TFO ICL insert was successfully ligated in small 
and then in large scale 
 
We did several small-scale ligation reactions in order to find the best 
condition that gives the highest yield of the final ligated product. Vector to insert 
ratio of 1:3 to 1:5 gave high yield of ligated final product in small-scale ligation 
reaction (Figure 22). A small amount of unligated or linear products and some 
multimers were observed. A 1:5 vector to insert ratio was utilized, and a large-
scale ligation reaction was performed (Figure 23). The substrate was purified by 
cesium chloride gradient to separate and purify the closed circular double 
stranded DNA (Figure 23). A 35 % yield of final ligated product was obtained. 
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4.3.4. Confirmation of the ICL in the final product 
 
After the final product was purified, we tested if it retained the TFO 
directed psoralen ICL. Small volume of the final product was restriction digested 
with BbsI and ran on a sequencing gel. The fragment released from the 
restriction digestion was the ICL fragment (Figure 24). 50 bp linear duplex DNA 
was used as a control marker. This confirmed that the final ICL product is correct 
and pure TFO directed psoralen interstrand crosslink in closed circular double 
stranded DNA. 
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FIGURE 21. Vector with BbsI sites. 
A. Fragment of duplex DNA inserted between KpnI and XbaI sites in pUC19 in 
order to insert BbsI restriction digestion site. Fragment with BbsI site is shown in 
the inset.  Blue and Red indicate the nucleotides for respective restriction 
digestion sites mentioned in the diagram. Green indicates the TFO binding site. 
Modified plasmid after the new insertion is called pUC19N. B. Denaturing 6% 
polyacrylamide gel with restriction digested pUC19N. Linear vector is shown in 
the inset and the lower band is the 50 bp fragment released for the restriction 
digestion. 
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5’ CGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGC 3’ 
    3’ CGAGAAGTAGGAAGGGGGGGGTGGTGGGGGAGGGGGAGCTTCTGCGCACG 5’ 
!!!!!!!!!!!!!!!!!!!!!!!!    5’AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG-NH2 3’ 
C
3'
5'
5’HMT-AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG-NH2 3’ B
5'
3'
KpnI XbaIBbsI BbsIA
                        TTCGAGCTCGGTACCGAAGACATCGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGCGTGCTCTAGAGTCGACCTGCA  
                        AAGCTCGAGCCATGGCTTCTGTAGCTACGAGAAGTAGGAAGGGGGGGGTGGTGGGGGAGGGGGAGCTTCTGCGCACGAGATCTCAGCTGGACGT ! !!!
!
!
A. 
B. 
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Different ratios of vector to insert were tested to get the highest yield of the  
ligated product. The final ligated product is a closed circular double-stranded 
DNA with a TFO directed psoralen interstrand crosslink. Purified pUC19N and 
purified vector were used as controls. The final product migrated in 1% agarose 
gel similar to pUC19N (2739 bp). Some unligated linear vector and some 
multimers were also observed in lesser quantity compared to the ligated closed 
circular DNA.  
  
FIGURE 22. Small scale ligation reaction with BbsI-vector and 50 bp pso-
TFO ICL. 
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FIGURE 23. Large-scale ligation reaction of BbsI-vector and 50 bp 
psoralen-TFO ICL insert. 
A. Ligation reaction on a 1% agarose gel right after the ligation reaction. Most of 
the products were closed circular DNA, indicated by the arrow. The bands above 
the final product are linear and multimer DNA. B. Large scale ligation reaction on 
a 1% agarose gel after purification by cesium chloride gradient. The linear and 
multimer DNA were reduced largely after purification. 
  
	   
B. 
A. 
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A. Diagram of the final ICL substrate with the nucleotide arrangement of TFO and
duplex DNA.  Green represents the nucleotides of the TFO binding site. TFO 
bound to the first two strands (duplex DNA) with Hoogsteen hydrogen bonding 
represented by the asterisk (*) marks. Gray dots represent Watson and Crick 
hydrogen bonding. Red represents the psoralen bridge between two thymines. B. 
Restriction digested final product was run on a denaturing 6% polyacrylamide 
gel. The released product ran as 50 bp psoralen-TFO products. 50 bp duplex 
DNA was also used as control.    
A	  
B	  
!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!5’ AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG-NH2 3’ 
                     5’CGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGC 3’     
                               3’CGAGAAGTAGGAAGGGGGGGGTGGTGGGGGAGGGGGAGCTTCTGCGCACGAG 5’ 
 
FIGURE 24. Confirmation of the final purified TFO- directed psoralen ICL in 
a closed circular duplex DNA. 
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4.4. Plasmid relaxation assay 
 
The closed double stranded DNA is the relaxed form of the plasmid. 
Experiments were performed to determine if the whole cell extracts process the 
supercoiled or relaxed form of DNA substrates differently. We incubated the 
plasmids in the presence and absence of whole cell extracts, and in NER 
reaction buffer and ran in gels with and without ethidium bromide. We found that 
the whole cell extract relaxes the plasmid within 5 minutes of incubation (Figure 
25). Whole cell extracts convert the supercoiled plasmid to the relaxed plasmid, 
which runs slightly faster than supercoiled plasmid in agarose gel without 
ethidium bromide (Figure 25A). When gel is run with ethidium bromide, ethidium 
bromide gets intercalated between the two strands of the relaxed plasmid, which 
makes it run slower than the supercoiled plasmid (Figure 25B).   
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pUC19N plasmid was incubated with or without whole cell extract in an ATP 
regenerating system, purified, and ran in  1% agarose gels with or without 
ethidium bromide.  A. 40 µg/100 mL ethidium bromide was run for 2 hours at 80 
V. B. without ethidium bromide; run for 2 hours at 80 V, and stained with 40 
µg/100 mL ethidium bromide for 20 minutes. pUC19N and Hyperladder were ran 
as markers. SCC indicates supercoiled closed circular, RCC: relaxed closed 
circular, NC: nicked circular, IR: intermediate relaxed DNA.  
  
FIGURE 25. Plasmid relaxation assay. 
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14% sequencing gel showing 3’ incision products on upper strand with G-
overhang labelling oligonucleotides to detect incision products at TFO 
binding site (A), beyond TFO binding site (B) and at 3’ side on the lower 
strand (C). Sequence mapping of the incision sites is shown in Figure 13. 
Darker bands marked with arrows are the major incision products. M 
denotes marker. Lanes with ICL substrate or with undamaged plasmid are 
labelled.  
20 bp 
30 bp 
40 bp 
50 bp 
100 bp 
ICL	  M 
15	  bp 
20	  bp 
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  bp 30	  bp 
35	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50	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ICL	  M	  	  +	  	  	  	  	  	  -­‐ A	   B	   C	  
FIGURE 26. 3’ Incision assay on psoralen-TFO ICL substrate. 
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FIGURE 27. Sequence-map of the incision sites. 
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Positions of incision sites are marked by the arrows and are corresponding to 
and color coded with the incision products shown in Figure 12. 3’ incision sites on 
the upper strand within TFO binding site are shown in (A) and beyond TFO 
binding site in (B), and lower strand in (C). Green sequences are TFO and red 
sequences are G-overhang oligonucleotides. Restriction digestion enzymes used 
in each experiment to prepare the ends for G-overhang complementary labelling 
with radiolabelled dCTPs are mentioned at respective DNA ends. Thymines 
involved in psoralen ICL formation are presented as bold ‘T’. Dashes denote the 
continuity of the sequences. 
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4.5. Incisions were observed on the 3’ side of psoralen-TFO ICL on both 
strands 
 
Incision assays were performed using a G-overhang oligonucleotide to 
detect the incision products at the 3’ side of the ICL crosslink. G-overhang 
oligonucleotides were used to detect the incisions at two different sites. One 
covered the site inclusive of TFO binding site and the other covered the area 
outside of TFO binding site. Incision products were not detected with the 
oligonucleotide at the TFO binding site, which suggests that the incisions did not 
occur at the TFO binding site (Figure 26A and 27A).  
 
G-overhang oligonucleotide end labelling detected incision products were 
represented by three dark bands and several faint bands on the upper strand. 
The bands were 22, 23 and 24 oligonucleotides long, and were mapped 10, 11, 
and 12 nucleotides away from the TFO, and 44, 45, and 46 nucleotides away 
from the psoralen ICL (Figure 26B and 27B). These dark bands were absent on 
the undamaged DNA substrate indicating that these incision products were 
specific to psoralen-TFO ICL on closed circular DNA. Similarly, 3’ incision assays 
were performed targeting possible incision products on the lower strand of the 
psoralen-TFO ICL substrate. Several dark bands appeared in the ICL substrate 
lane, which were not present in the undamaged substrate lanes. The bands were 
observed as 18, 19, 20 and 21 oligonucleotides long and were mapped at 8, 9, 
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and 10 nucleotides away from the ICL site (Figure 26C and 27C). The repetition 
of the assays also showed several dark bands around the same sites.  
 
4.6. Psoralen-TFO ICL was not repaired by HeLa whole cell extract 
 
Repair assay based on the translesion synthesis at the damaged site by 
the repair polymerases was performed in order to see if the incisions observed in 
above experiments were for the repair-purpose. In other words, by repair assays, 
we wanted to see if the human cell extract can repair TFO-directed psoralen ICL 
in closed circular double stranded DNA. Repair assays were done in similar 
reaction conditions as incision assays except that the reactions included 
radiolabelled dNTPs to be incorporated by the polymerases for the repair. The 
repaired products were restriction digested, and fragments were analysed if they 
incorporated radiolabelled dNTPs. After the repair reaction, restriction digestion 
enzymes (AluI and SapI) were used to create different sized fragments to make it 
easier to be analysed on sequencing gel. 29 bp and a 69 bp fragments from the 
restriction digestion were supposed to have incorporated more radiolabelled 
dNTPs compared to neighbouring fragments and compared to undamaged DNA. 
We did not observe any 29 bp bands in ICL substrate however, it was observed 
in undamaged plasmid (Figure 28). SapI sequence was present at the site of 
psoralen ICL. Thus it is possible that the ICL substrate was not repaired and was 
resistant to SapI. Since a 69 bp band was not resolved well in a 14 % 
sequencing gel, it could not be analysed.  
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We performed another repair assay with the same principal as the above 
repair assay except that the restriction digestion enzymes were different. This 
time, we used BbsI and MluCI. A 50 bp band was supposed to have been 
repaired, and have incorporated radiolabelled dNTPs as it included the site of 
damage. Unlike our expectation, a 50 bp band was missing from ICL substrate 
whereas other neighbouring bands; 25 bp and 68 bp bands were observed 
(Figure 29). These fragments were possible only if both BbsI and MluCI cut at 
their respective sites. This indicated that BbsI could cut at the designated site 
and released the fragment consisting of ICL but no new dNTPs were 
incorporated for repair at this fragment. Repair synthesis assay for cisplatin 
substrate in HeLa whole cell extract as described earlier was used as control 
assay.  Control assay showed a 33 bp high intensity fragment indicating the 
successful repair synthesis happening on cisplatin substrate as described earlier. 
This result was reproduced in repeated experiments indicating that TFO-directed 
psoralen ICL was not repaired by HeLa whole cell extract.  
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FIGURE 28. Repair synthesis assay 1. 
A. 14 % sequencing gel showing restriction digested fragments after repair 
synthesis assay on psoralen-TFO ICL or pUC19N plasmid. Lanes 2, 4 and 6 are 
repair reactions with ICL substrate for 30 min, 1 hr and 3 hr, and lanes 1, 3 and 5 
are with undamaged DNA for 30 min, 1 hr and 3 hr respectively. B. Map of 
fragments made by AluI and SapI enzymes. AT is the site of ICL formation where 
SapI sequence coincides. 
A. 
B. 
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FIGURE 29. Repair synthesis assay 2. 
A. 14 % sequencing gel showing restriction digested fragments after repair 
synthesis assay on psoralen-TFO ICL or pUC19N plasmid (Lanes 5,6) or 
cisplatin intrastrand crosslink substrate (Pt) or undamaged DNA as control for Pt 
substrate (Lanes 1-4) as control. Lanes 3 and 4 were performed without whole 
cell extract for control. Purified DNA from repair assay with or without Pt samples 
were restriction digested with BstN1 (lanes 1-4) and with or without ICL substrate 
was restriction digested with BbsI and MluCI (Lanes 5 and 6). B. Map of 
fragments created by BbsI and MluCI on ICL substrate.  
  
A
. 
B
. 
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Chapter 5. Discussion 
 
5.1. Consequences of XPA disruption in human cells  
 
5.1.1. Expression of a subset of genes is influenced by XPA status in cell 
lines 
 
 The major purpose of this study was to determine the extent to which 
XPA status may influence transcriptional activity in cells. As we show here, 
expression of a restricted subset of genes is reproducibly affected by XPA status. 
These include genes that are necessary for steroid metabolism and for optimal 
mitochondrial function and integrity. 
 
 A plausible explanation for a positive effect of XPA on gene expression is 
that XPA acts as part of a transcription factor complex, for this subset of genes. 
For example, by binding to DNA and proteins in concert with the transcription 
initiation factor TFIIH and other NER proteins, it may modulate TFIIH activity for a 
subset of genes. As XPA is a DNA binding protein, it might also serve as a 
component of an enhancer or mediator complex for some genes. 
 
 Another, not necessarily exclusive possibility is that the NER defect 
caused by XPA deficiency gives rise to constitutive DNA damage stress that 
interferes with transcription of some genes. Persistent sites of DNA damage on 
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templates will interfere with transcription. For individual genes that are more 
susceptible to DNA damage, this could account for the higher transcription of 
some genes in XPA-proficient cells.  Graphic explanation of some possible 
mechanisms by which XPA may be involved in transcription is presented as a 
model in Figure 30. 
  
What are possible sources of DNA damage that would result in 
constitutive stress for XPA defective cells? A low yield of UV radiation-induced 
pyrimidine dimers could potentially accumulate in XPA-defective cells from UVA 
radiation that can penetrate plastic dish lids. However, we take care to culture 
cells in low ambient light or with yellow fluorescent lights, and this seems unlikely 
to be a significant source of stress to explain our data. A ubiquitous and 
constitutive source of damage is the lesions caused by reactive oxygen species, 
constantly produced in cells. Reactive oxygen species induce many lesions that 
are largely repaired by XPA-independent BER. However, one type of oxidative 
damage, the 8,5'-cyclopurine-2'-deoxynucleosides (cyclopurines), are repaired by 
NER but not by BER (78, 79). These lesions are known to interfere with 
transcription. 
 
 Oxidative damage, particularly cyclopurine lesions, has been previously 
suggested as an explanation for the neurodegeneration in XP patients (76, 78, 
120), which includes progressive cerebral atrophy and hearing loss. Most 
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neurons are non-replicating and metabolically very active, depending on 
mitochondria to remain functional.  
 
On the other hand, there are contradictions about oxidative damage 
accumulation in XPA mutant causing of neurodegeneration and accelerated 
aging as shown by studies in C. elegans (121). Deficiency of XPA did show 
accumulation of oxidised base like formamidopyrimidines (122) however, xpa-1 
mutants were found to have normal life span (121, 123). This study suggests that 
there may be mechanism other than defect in DNA repair in XP patients that 
causes neurodegeneration and accelerated aging.  
 
 A more direct connection between an increased load of DNA damage and 
mitochondrial dysfunction is also possible. There are several examples of this. In 
mice, a telomerase defect eventually gives rise to exposed telomeres. This 
genomic stress is clearly associated with mitochondrial dysfunction, and it is 
possible that exposed DNA ends mimicking a DSB induce a signal for disruption 
of key mitochondrial genes (124). An siRNA screen for factors that reduce 
sensitivity to a mitochondria-targeted DNA damaging agent provides another 
example (125). A diversity of different DNA repair factors, including XPA were 
detected in this screen. 
 
 With an increased load of DNA damage, transcription may be delayed 
because template damage interferes with transcript elongation. A second 
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consideration is that transcription and NER are competing processes. For 
example, transcription initiation efficiencies in yeast are reduced when NER is 
ongoing (126). In mammalian cells, there is lower NER activity at promoters 
when core transcription factors are bound to them (127, 128). After UV radiation 
damage to DNA, NER proteins are delayed in recruitment to promoter sites by 
several hours (81). This suggests that NER proteins are prioritized to repair 
damaged DNA first before resuming any activity in transcription. 
 
5.1.2. Defective mitophagy associated with XPA deficiency and relation to 
neurological deficits 
 
 It has been observed that some of the symptoms of xeroderma 
pigmentosum group A have commonalities with mitochondrial disorders (82). 
Their study showed in human cells defective of XPA protein, mitochondrial 
functions like mitochondrial membrane potential, membrane organization and 
oxidoreductase activity were abnormal. XPA was reported to play a role in the 
regulation of mitochondrial autophagy and mitochondrial functions through 
NAD+/SIRT1 and PARP (82). In the present study, we found that genes 1.5 fold 
or more changed in XPA+ compared to XPA- were indeed significantly 
represented for many mitochondrial and mitophagy-related GO terms (Table 4). 
   
 Mitochondrial defects and mitophagy are directly related to neurological 
functions. About 25 % of xeroderma pigmentosum patients develop 
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neurodegeneration in later life. The progressive neurodegeneration includes 
intellectual defects, hearing impairment, abnormal speech, neuropathy and 
muscular discoordination for movements of hands and legs (129). In a study of 
XP patients from 1971-2009, 6 out of 10 patients with XP-A and 16 out of 23 
patients with XP-D had neurological degeneration (129). The cause of the death 
of many XP-A patients was also neurological degeneration (129-131). 
 
One possible reason for this phenotype is the accumulated DNA damage 
in metabolically active but non-dividing neurons (57, 129), whereas some study 
in C. elegans show that xpa-1 mutant, although accumulate oxidative damage, 
do have normal life span (122, 123). Other recent study shows that the xpa-1 
mutant old worms have higher amount of NAD+ production due to increase in 
PAPRylation, which may due to the mitochondrial dysfunction (82). This result 
suggests that there is a relation of old-age with mitochondrial dysfunction, which 
is more prominent in XPA deficient condition. Overall, these studies suggest that 
XPA may have role in maintenance of mitochondrial functions and consequently 
neurological functions. 
 
5.1.3. The most significant XPA-regulated genes may explain steroid and 
sexual degeneration issues in xeroderma pigmentosum group A 
 
The genes that are uniformly altered with the highest magnitude and 
significance are AKR1C1 and AKR1C2. These genes are critical for steroid 
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metabolism and some bile metabolism (132-134). AKR1C1 converts 
progesterone to its inactive form, 20-alpha-dihydroxyprogesterone. AKR1C2 
catalyzes the inactivation of the most potent androgen, 5-alpha-
dihydrotestosterone, to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol). 
Therefore, an imbalance of steroid hormones may be expected in XPA-defective 
cells. Both genes are indeed associated with obesity, sex reversal, hyperphasia 
and developmental delays (135, 136). A previous study using microarray analysis 
to study gene expression changes in XPA-defective cells (82). We analyzed the 
most XPA-dependent genes found in this microarray analysis (NCBI GEO 
dataset GSE55486) and compared it to our list of most changed genes. AKR1C2 
was the only gene that coincides with our list of most changed genes by RNA-
Seq analysis. We confirmed that XPA-deficient cells have exceptionally low 
levels of AKR1C1 and AKR1C2 at the protein level, compared to proficient cells. 
This was true in both fibroblasts and HeLa cells.  
 
 Our finding of XPA-dependent expression of the steroid regulator AKR1C1 
and AKR1C2 gene products may be highly relevant to the sterility and sexual 
developmental issues observed in XPA-deficient mice (137). Degenerating 
seminiferous tubules and no spermatozoa were detected in 24 month old XPA-/- 
mice (137). Secondary sexual development is delayed in some XP patients 
(138). Consequently, our finding of XPA-dependent expression of the steroid 
regulators AKR1C1 and AKR1C2 may be highly relevant to the sterility and 
sexual developmental issues observed in mammals. 
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5.1.4. Multiple non-isogenic cell lines improve the analysis of RNA-Seq data  
 
Despite these correlations, there are many unanswered questions concerning the 
mechanism of how XPA affects mitochondrial function. One puzzle is that 
although mitochondrial functions are affected, the specific gene transcripts that 
are affected are different in each cell line pair. Our current study shows how 
important it is to not only have biological replicates for RNA-Seq, but also to 
investigate cell lines of different genetic background in order to uncover the most 
significant effects of a single gene disruption. 
 
5.1.5. Possible additional role of XPA may not be related to NER 
 
It is significant that the XPA-dependent transcriptional profiles in KO142 
and KO48 cells are similar, even though KO142 cells retain about 10% of the 
XPA protein level found in HeLa cells. The amount of XPA present in the KO142 
line is enough to confer near-normal UV sensitivity, consistent with previous 
findings that XPA is in excess in cells for NER activity (116). Because complete 
knockout of XPA or knockdown to 10% has a similar effect on transcription, this 
suggests that at least part of the influence of XPA on transcription is not directly 
related to the NER function. 
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5.1.6. Cause of XPA instability in KO142 
 
We checked if the loss of XPA protein in KO142 is due to the proteasomal 
degradation. Our result did not indicate such possibility although this study needs 
to be repeated with proper control for proteosomal degradation. Another cause of 
less XPA in KO142 may be due to the alternative splicing. The six amino acid 
deletion may have created an exonic splicing enhancer or disrupt exonic splicing 
silencer that could lead to an activation of alternative spicing site causing some 
exon skipping. This can be tested by PCR using one primer at Exon 1 and other 
one at different positions on exons beyond hypothesised splice sites. The 
products can be run in gel to compare the products from different pairs of 
primers.   
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1. XPA may be involved in transcription by its interaction with TFIIH. 2. XPA may 
directly bind to the promoter to directly play role in transcription. 3. XPA may bind 
to the enhancer region and be involved in transcription as a co-activator. 4. Due 
to unavailability of XPA for the DNA repair at the promoter site, transcription may 
be obstructed or delayed.  
  
FIGURE 30. Model: Possible mechanism by which XPA is involved in 
transcription. 
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5.1.7. Future directions 
 
5.1.7.1. Validation of RNA-Seq results by immunoblotting and CHIP 
   
  This study is the initial effort to get an idea of the extent of transcriptome 
changes in XPA-defective human cells. Our result shows that a small percentage 
of genes is affected by the XPA status. We found by RNA-Seq analysis that a 
high percentage of affected genes represented specific functions related to 
mitochondrial regulation and pathways related to neurological functions. We 
validated some of the important genes from RNA-Seq result at protein level and 
verified 2 of the three tested targets. However, this is only a small percentage of 
genes out of 27 highly differentially expressed genes in XPA- vs. XPA+. In the 
future, it will be valuable to check all of the 27 genes at the protein level.  
  
  Another way of validating the results from RNA-Seq will be to perform a 
chromatin immunoprecipitation (ChIP) assay at the promoter sites of the highly 
differentially expressed genes like AKR1C1, AKR1C2, and more genes of 
interest, to see if XPA is present at the promoter sites of these genes. This will 
give an idea about the mechanism how XPA is involved in the transcription. 
Since it has also been observed that in retinoic acid transactivated conditions, 
not only XPA but many other NER proteins were also found at the promoter 
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regions of few genes (81), it will be worth to look at if other NER proteins can 
also be pulled down.  
 
  The cell lines we used in our study are immortalized or cancer cell lines. It 
is important to get similar results in the primary cell lines as well to make sure the 
change in the genes are not related to the immortalization. Validations of the 
highly differential genes by similar methods as mentioned above can be done in 
the XPA deficient primary cell (skin fibroblasts) lines and normal human skin 
fibroblast as control. Comparison with primary cells from other XP groups would 
confirm that the changes are XPA-specific. 
 
5.1.7.2. Analyzing differentially expressed genes in XPA deficient mice  
  
In XPA-deficient mouse models, male sterility was one of the characteristics 
noted (139). However it not known whether the XPA-dependent genes that we 
found by RNA-Seq are involved in phenotypes of such mice. As AKR1C2 
deficiency is found to be one of the causes for the reversal of sexual orientation 
and sterility (140), it will be valuable information to look for AKR1C2 and other 
genes of our interest in tissues of XPA deficient mouse models.  
 
5.1.7.3. Biochemical assays for mitochondrial and metabolic functions in 
XPA deficient and proficient cells 
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  Since we found metabolic and mitochondrial pathways being represented 
by significant differentially expressed genes in our analysis, XPA may have a role 
in metabolism or mitochondrial maintenance. It is worth looking into more details 
of XPA being involved in mitochondrial functions by performing biochemical 
assays. Monitoring ATP generation, mitochondrial membrane potential, ROS 
formation and biochemical metabolic reactions such as reduction of aldehyde-
ketone compounds in XPA deficient cells compared to the proficient, can be done 
for the further insight in the study. Immunofluorescent assays can also be done 
to compare the expression of these genes like NDUFA4L2 (NADH 
Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex, 4-Like 2) compared to XPA 
status.  
  Although it needs more study, we obtained some preliminary results for 
the influence of XPA status on mitochondrial functions. We performed 
biochemical assays to detect the mitochondrial mass, mitochondrial membrane 
potential defect and amount of ROS levels in XPA proficient and deficient cell 
lines. Following assays were performed in collaboration with Dr. Miao-der Chen 
in Bratton laboratory. 
 
Mitochondrial mass:  
  To determine whether the mitochondrial dysfunction obtained suggested 
by expression pathway analysis is due to a low mitochondrial mass in XPA 
deficient cells, we looked at the total mitochondrial mass in all cells. Cells were 
treated with TMRE (tetramethylrhodamine, ethyl ester) dye for 5 min at 37 °C, 
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washed with PBS and subjected to Flow cytometer (Accuri C6 Flowcytometer) 
using FL3 fluorescence channel and 8000 events (141). TMRE is a positively 
charged red dye that is accumulated easily in mitochondria due to its negative 
charge. Depolarized or inactive mitochondria have low membrane potential and 
are unable to pump in the dye (142). We observed no difference in the total 
fluorescence count (total populations) in XPA proficient and deficient cells except 
slight lower count in XP12RO compared to XPA/XP12RO cells (Figure 31A). This 
result indicated that there is no difference in number of mitochondria in XPA 
proficient and deficient cells. Cells not treated with TMRE were used as negative 
control and they were observed as population without fluorescent counts. This 
assay needs to be repeated to confirm the result. 
 
Mitochondrial membrane potential defect:  
  To confirm the result about defect in mitochondrial membrane potential in 
XPA deficient cells from the pathway analysis, we performed similar assay as 
described above and looked at the population that could not pump in TMRE in 
the mitochondria. This population represents the defect in membrane potential 
(143). We observed that XPA deficient cells have higher percentage of 
population that has defect in mitochondrial membrane potential compared to the 
proficient cells. This population has low mitochondrial membrane potential 
(Figure 31B). Similar negative control was used as mentioned above. This assay 
needs to be repeated for the confirmation of the result. 
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ROS levels: 
  Higher ROS production is one of the factors observed when there is defect 
(high) in mitochondrial membrane potential. We performed an assay where a 
reagent  (CM-H2DCFDA) for indicator of ROS was used in cell culture at 37 °C 
for 15 min. It turns to fluorescent compound DCF after oxidation, which was 
measured by flow cytometer at fluorescent channel FL1 and 8000 events. Cells 
not treated with CM-H2DCFDA were used as negative control. We did not 
observe difference or only little lower ROS in XPA deficient cells compared to the 
proficient cells (Figure 31C) which is relevant to the lower mitochondrial 
membrane potential observed in Figure 31B. This result indicated that the cells 
are not going through the oxidative stress. This assay needs to be repeated for 
the confirmation of the result.  
  
  Our preliminary results mentioned above contradict with the recent study 
in XPA deficient human cell lines showing the increased mitochondrial potential 
and ROS levels in XPA deficient cells (82). If our result is true about lower or no 
difference in ROS level in XPA deficient cells, it could be because the XPA 
deficiency is not causing problem for repairing of the oxidative damages, as BER 
is efficient enough to repair most of the oxidative damages.  
 
  Both low and high mitochondrial potential are defective for cells as they 
have abnormal physiological consequences (144, 145). If our result about lower 
mitochondrial membrane potential in XPA deficient cells compared to XPA 
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proficient cells is true, it may indicate that the XPA deficient cells are going 
through low generation of ATP or low oxidative phosphorylation. This explanation 
also concurs with the high fold change (1.5 - 7) in NDUFA4L2 gene in XPA 
proficient cells compared to the deficient. This result suggests that XPA may play 
role in metabolism by maintaining mitochondrial membrane potential.  
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FIGURE 31. Mitochondrial assays. 
Defective	  mitochondrial	  membrane	  potential 
A	  
B	  
C	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A. Mitochondrial mass was measured by the fluorescent count produced by the 
uptake of TMRE dye in the mitochondria. B. Defect in mitochondrial membrane 
potential was measured as indicated by the population in the flow cytometer read 
that were unable to sequester TMRE dye in the mitochondria by the membrane 
potential pump. C. Level of ROS in the cells was measured as indicated by the 
fluorescent count produced due to the oxidation of CM-H2DCFDA in to DCF.    
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5.1.7.4. Analyzing brain tissues of XPA deficient mice and patients with 
neurological diseases  
 
  Similarly, we observed many genes and pathways responsible for 
neurological functions. It is also important to explore XPA in vivo analysis. This 
can be studied in brain tissues of XPA deficient mice in absence of any external 
DNA damage and also observe these changes regarding some of the 
neurological genes such as WFDC21P, LHX2, HOMER2 and others we observe 
as highly expressed in XPA proficient cells. Immunofluorescent assays on brain 
tissues for the expression of these genes compared to XPA will be helpful to 
understand the effect of XPA status in neurological functions. Alternatively, tissue 
samples from patients with Alzheimer’s or Parkinson or Huntington disease can 
be analyzed for the expression of XPA. The result will be helpful in further 
discussing on the cause of neurological defects in XPA patients.    
 
5.2. Processing of TFO-directed psoralen interstrand crosslink in human 
cell extracts 
 
5.2.1. Psoralen-TFO ICL or TFO as an adduct for NER 
 
  The enzymatic processing of a TFO-directed psoralen ICL in closed 
circular double stranded DNA has not been studied previously human cells. It is 
highly possible that it is a substrate for NER in human cells as the mutation 
caused by TFO was found to be dependent on NER (146). In non-replicating 
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conditions, damage in DNA is recognized by NER as distortion to DNA structure. 
Psoralen causes enough distortion in duplex DNA, which makes it a substrate of 
nucleotide excision repair, even though the distortion is less than other ICL 
causing agents such as cisplatin (22). It makes a large 55.8° buckle in the d (T.A) 
base pair with thymine on the pyrone strand. This results in a steric collision of 
the O4 of thymine and pyrone ring, resulting in destruction of Watson and Crick 
hydrogen bond between the base pairs (147). We used the TFO conjugated 
psoralen primarily to construct a site specific ICL. However, since both psoralen 
and TFOs may be substrates for NER, we expected the processing of TFO 
directed psoralen ICL substrate may be dependent on NER. The addition of TFO 
to psoralen may cause even more degree of distortion compared to that caused 
by TFO or psoralen alone. This may be the reason why we observed incisions 
only beyond the TFO binding site on the strand (upper), where TFO is bound to 
the DNA. On this strand, incision products were observed 44 nucleotides away 
from the ICL site, which were beyond TFO binding site. These incisions were 9 
nucleotides or farther from the 3’ end of the TFO, which is relevant to the 
distance of 3’ side incisions observed with cisplatin intrastrand adduct in human 
cells (102). We also tried to detect incision products within TFO binding site, but 
we were unable to find any incisions within TFO binding site. This result may be 
the indication that TFOs are substrates for the nucleotide excision repair pathway.  
 
5.2.2. TFO-directed psoralen ICL was not repaired by HeLa whole cell 
extract 
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  We observed incisions at the 3’ side of TFO-directed psoralen ICLs but we 
were unable to detect repair in human cell extract. We did not find incorporation 
of radiolabelled dNTPs at the ICL site, which was indicated by the disappearance 
of the fragment containing the ICL in the damaged DNA substrate compared to 
the undamaged DNA substrate. In one of our repair assays, we used a restriction 
site that coincides with the ICL formation site, which makes the ICL substrate 
resistant to the restriction digestion by SapI. 29 bp and 69 bp fragments were 
supposed to be released if SapI and AluI cut at their sites. We found the 
disappearance of the 29 bp on ICL substrate whereas we could not confirm 
similar result for the 69 bp fragment, as it appeared to be coinciding with other 
bands (64 and 67 bp) on the gel.  
  
  We designed another repair assay with different restriction digestion sites. 
Since we were confident that BbsI cuts and releases the 50 bp ICL fragment, we 
used BbsI and one other site, MluCI, to create multiple bands to make the 
comparison of intensity of the fragments more efficient. In this assay also, we 
found the ICL containing fragment (50 bp) was not observed on the ICL substrate, 
whereas it was observed on the undamaged plasmid. Since all other neighboring 
bands were also observed in both damaged and undamaged DNA, the restriction 
digestion was successful with both enzymes but the 50 bp ICL fragment was not 
replaced with the radiolabeled dNTPs. This result suggests an unsuccessful 
repair of the psoralen-TFO ICL in HeLa whole cell extracts.  
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  This turns our attention towards the question whether the incisions we 
observed in human whole cell extracts are repair-related. If they are not for the 
purpose of repair, why are the incisions made? It could be that the cell extracts 
cannot proceed beyond incision to complete the repair on psoralen-TFO ICL. 
However in mammalian cells, previous studies have indicated the repair of TFO 
or psoralen ICL or psoralen-TFO ICL. TFO-induced mutation was dependent on 
NER (XPA) (146), and thus TFOs are possibly repaired by human cells. Psoralen 
ICLs are also repaired in human cells as shown by reporter assays (148). TFO-
directed psoralen in mammalian cells has shown to cause a higher degree of 
mutation compared to spontaneous mutation (149), indicating its recovery. 
However, no study has been done so far to study the repair of psoralen-TFO ICL 
in human cell extract. If TFO-directed psoralen ICLs are not repaired by the 
whole cell extracts, but are repaired in human cells, it may be because they are 
processed beyond incision by other DNA repair enzymes besides NER proteins. 
Recently it has been reported that NEIL3 glycosylase is involved in unhooking of 
psoralen ICL in xenopus egg extract in incision independent way (150). When N-
glycosyl bond cleavage is inhibited, the incisions were produced in a FANCI-D2 
dependent manner (replicating system), indicating that the NEIL3 unhooking is 
the preferred way of processing psoralen ICLs in vertebrate cell free system. 
Thus it may be possible that psoralen-TFO ICLs are also processed by NEIL3 at 
the unhooking step. In absence of this step in processing, repair may not have 
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occurred in HeLa whole cell extract. The possible mechanism by which psoralen-
TFO ICLs are processed in human cells is represented as a model in Figure 32. 
 
5.2.3. TFO in targeted DNA damage and gene alteration 
 
   We have not tested the difference between incision products with psoralen 
only and psoralen-TFO ICL. If it is true as observed in E.coli where TFO resulted 
in more incision products than psoralen ICL only (25), psoralen-TFO ICL may be 
more effective in chemotherapy to kill cancer cells through DNA damage. Thus, 
determining the mechanism of TFO-directed psoralen-DNA ICL is an important 
step towards improving chemotherapy.  
  
  Currently, due to lack of specific targets, chemotherapies are not being 
effective. TFOs can be used to target specific genes, like oncogenes, to disrupt 
them or to deliver targeted drugs like antimetabolites to specific sites to cause 
cytotoxic effects in cancer cells (151). Since TFOs bind to specific sequences of 
the genome and with high affinity, it has been put forward as an option for 
altering targeted sequences (152-155). It can lead to improving the cure and 
treatment of different genetic diseases. There is an abundance of TFO-binding 
homopurine or homopyrimidine rich sequences present in human genome (156), 
giving a good platform for TFO-targeting treatment. TFOs can be used in 
conjugation with DNA damaging agents, such as ICL causing agents or photo 
induced endonucleases (157) for the targeted effects. The concept of TFO 
146 	  
conjugated drug therapy is still not implemented in humans. In mice, cells 
transfected with TFO conjugated with a cytotoxic drugs was delivered to treat 
tumors, and was successful in reducing the tumor load (151). Similar strategy 
can be used to deliver TFOs, TFO conjugated drugs, or DNA damaging agents in 
cancer patients. However, since it is not exactly known about the mechanism of 
processing of TFO or TFO conjugated psoralen, the results from TFO-targeting 
therapy will be highly unpredictable.   
 
5.2.4. ICL substrate in a closed circular double stranded DNA 
 
  Most of the efforts to study the processing of ICL were done with ICL in 
short duplex DNA. Since the duplex DNA has open ends, it is possible to be 
processed by unspecific nucleases available in the cell extract. To avoid the 
artifacts and confusions of processing of ICL due to the accessibility of the free 
ends, we constructed ICL in closed circular double stranded DNA and purified 
high-yield of the final product. It was also important to purify ICL products from 
the monoadducts, which are formed during the photoactivation of psoralen. It 
was even more challenging to do this purification with closed circular double 
stranded DNA. Thus we first made ICL in short duplex DNA, purified in 
denaturing condition as covalent bonding in ICL cannot be separated by 
denaturing while DNA with monoadducts can be separated to single stranded 
DNA. Short duplex DNA with ICL purified by this strategy was efficiently ligated to 
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the vector with unique DNA ends (BbsI) to confirm the correct orientation of the 
ligation.  
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The damage is recognized and incisions are made around the psoralen-TFO ICL, 
which may be dependent on NER. The gap created by incisions is repaired by 
translesion synthesis. In the later step of repair, unhooked structure is formed 
which may be cleaved by NEIL3 followed by repair by DNA polymerase and 
ligase.  
 
 
FIGURE 32. Model: Possible mechanisms of psoralen-TFO ICL repair in 
human cells. 
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5.2.5. Future directions 
 
5.2.5.1. Incision assay with NER deficient cells complementation with 
purified XPA protein 
 
  There are some indications from the previous studies that the incisions we 
observed with the psoralen-TFO ICLs may be dependent on NER. However, we 
have not ruled this out for certain. The important study to do in the future will be 
to confirm this with NER deficient whole cell extracts and complement with the 
purified NER protein. XPA deficient whole cell extracts from KO38 cells will be 
made, and the incision reactions will be performed as described earlier, with or 
without addition of XPA purified protein.  
 
5.2.5.2. Detection of 5’ side incisions   
 
  We looked for the incision products only at the 3’ side of the adduct, on 
both strands. Detection of the incisions at the 5’ side of the psoralen-TFO ICL, in 
similar process as we detected 3’ incision sites, is a challenge due to the 
direction of the polymerase activity and the limited restriction digestion sites 
available on the plasmid. An effective plan should be developed to detect the 
incision products at the 5’ side as well. Only after confirming that the incisions 
occur on this ICL substrate at both sides of the adduct, we could be more close 
to understanding if the processing of the TFO-directed psoralen ICL in closed 
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circular double stranded DNA is by NER. Some strategies are presented as 
follows: 1). Design a G-overhang oligonucleotide complementing incision product 
around between ICL and ClaI. This is only 10 bp long distance, which may be too 
short to cover the incision site at 5’ side of the ICL. Another G-overhang can be 
designed around EcoRI, which is 37 bp away from the ICL, and may be too far to 
cover the incision site. However we have not tried this and it may be worth trying.  
2). In another strategy an oligonucleotide can be designed in which its 3’ end 
coincides with the 5’ end of EcoRI, a restriction digestion site 37 bp away at the 5’ 
side of the ICL. The coinciding of the ends is important to exactly map the size of 
the incision product. The oligo should be long enough to cover the incisions close 
to 5’ side of the ICL. This oligo will be radiolabelled at its 3’ end. After the incision 
reaction of the DNA substrates, they will be purified, denatured, and annealed 
with radiolabelled oligonucleotide. A single strand specific nuclease will be used 
to digest the 3’ overhang resulting in the duplex DNA of same size as the incision 
product and will be detected in sequencing gel (Figure 33). 
  
5.2.5.3. Incision assays with or without TFO 
 
  Our results from the incision assay on psoralen-TFO indicated that TFO 
may be substrate for the incision reaction, but to differentiate if psoralen ICL and 
TFO-psoralen ICL are processed differently, TFO has to be removed after 
interstrand crosslink with psoralen is formed and the similar incision assays need 
to be performed and analyzed. A strategy as described in Christensen et al, 2008 
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can be used for this purpose (25). TFO and psoralen can be bound to a disulfide 
bond that can be easily removed after ICL is formed, by treating with DTT at 
60°C for few hours (158).  
 
5.2.5.4. Involvement of NEIL3 in the processing of psoralen-TFO ICL 
 
 NER proficient whole cell extract could not repair psoralen-TFO ICL in our 
experiments. It may be possible that other repair pathways are involved in the 
processing of the ICL substrate that the whole cell extract we prepared are not 
proficient in. Recently it has been reported that NEIL was cleaves the unhooked 
structure of psoralen ICL in incision independent manner (150). It is worth to 
check if psoralen TFO is also unhooked by NEIL3 after initial incisions are made. 
The reaction can be done following the protocol in Liu. M, et al, 2009 (159). 
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After the incision reaction, a 3’ radiolabelled oligo will be annealed to the purified 
and denatured DNA intermediate products of control substrate and ICL substrate 
indicated in the figure. A single strand specific nuclease will be used to digest the 
overhang of the oligo at 5’ side. The remaining fragment will be detected on a 
sequencing gel.  
  
FIGURE 33. Strategy to detect incisions at the 5’ side of the ICL on the 
upper strand. 
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